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Introduction and outline 
of the thesis
Chapter 1
INTRODUCTION 
This thesis describes several aspects of rheumatoid arthritis (RA) and osteoporosis 
and the link between them. The introduction of this thesis gives a description of both 
diseases and it addresses several aspects of the diseases that we investigated. 
Rheumatoid arthritis
Rheumatoid arthritis is a chronic systemic inflammatory disease that may affect many 
tissues and organs but that mainly affects the joints. RA is characterized by synovitis and 
destruction of the small joints of the hands and feet. The disease affects approximately 
0.5 to 1 percent of the Caucasian population and it has a peak incidence between the 
ages of 50 and 60 [1-5]. One of the other characteristics of RA is the presence of auto-
antibodies: IgM rheumatoid factor (IgM-RF) and anti-citrullinated protein antibodies 
(anti-CCP). 
The aetiology of RA remains unknown. There is, however, increasing evidence that 
anti-CCP plays a role in the development of RA. Citrullinated proteins are found 
in inflamed joints of RA and also, to a much lesser extent, in non-RA patients but 
antibodies against these proteins are highly specific only for RA patients. These 
antibodies can be detected in the serum of patients years before the development of 
the disease [7]. These findings strongly suggest a pathological role for the antibody 
response in the development of RA [8, 9]. 
RA can be a disabling and painful condition, which can lead to a substantial loss of 
function and mobility with an increased risk of morbidity and mortality [10-13]. This 
increased mortality is mainly due to an increase of deaths caused by cardiovascular 
diseases (CVD) [14, 15]. Another associated co-morbidity is osteoporosis: patients 
who tend to have a low BMD with an increased fracture risk. Inflammation, use of 
steroids and immobility seem to be the main risk factors. 
Disease Modifying Anti-rheumatic Drugs (DMARDs) are the choice for treatment of 
patients with rheumatoid arthritis. The ultimate goal for treatment is to achieve drug-free 
remission. Remission is defined as a state with no or little disease activity, no progression of 
joint destruction and no further loss of quality of life [16]. Treatment of RA has improved 
dramatically over the past decade. It has changed from a “start-low-go-slow” approach 
into a strategy of early intervention with more aggressive (combination) strategies and 
close monitoring aiming to achieve remission as soon as possible. This new approach is 
highly effective in controlling disease activity and preventing joint damage [17-19]. 
The introduction of the so-called biologicals is another big improvement in the 
treatment of RA. These drugs are made through biotechnology and they target specific 
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mediators in the inflammation process. Currently, biologicals are available against 
several pro-inflammatory cytokines (Il-1, TNFα and IL-6) and against B-cells and 
activation of T-cells. Biologicals against the pro-inflammatory cytokine Tumor Necrosis 
Factor (TNFα) were the first biologicals, introduced for use in clinical practice.
TNF blockers have shown to be able to control disease activity effectively and to reduce 
joint destruction, particularly when given in combination with methotrexate [20-23]. 
However, because of the powerful immune suppression by these biologicals there is 
an increased risk of infections (number and severity) during treatment, especially 
reactivation of tuberculosis [24, 25]. Another issue is that a number of patients with 
rheumatoid arthritis may lose their initial response to biologicals [26]. One of the 
possible reasons for this could be the formation of neutralizing antibodies against these 
drugs (human anti-human antibodies (HAHA) and human anti-chimeric antibodies 
(HACA)) [27].
Osteoporosis 
Osteoporosis is a disease, defined as loss of bone mineral density and a deterioration 
of micro-architecture leading to an increased risk of fractures [28]. Osteoporosis 
predominantly occurs in postmenopausal women: it is related to a lower peak 
bone mass in women and accelerated bone loss after menopause. Furthermore, life 
expectancy for women is higher than for men, which is also an important reason for 
a high fracture rate in women, because the incidence of fractures increases with age 
[29]. Fractures most frequently occurring in osteoporosis are wrist, hip and vertebral 
fractures [30, 31]. These fractures, especially hip fractures, have a major impact on 
quality of live and also on mortality rates [30, 32]. 
The diagnosis of osteoporosis is made by measuring bone mineral density (BMD) of 
hip or spine. BMD is measured using a dual X-ray absorptiometry machine (DXA). 
Osteoporosis is diagnosed when the bone mineral density is less than or equal to 2.5 
standard deviations in spine and/or hips, which is below the BMD of a young adult 
reference population. This is translated as a T-score. The World Health Organization 
has established the following diagnostic guidelines [33]: 
T-score -1.0 or greater is “normal” • 
T-score between -1.0 and -2.5 is “low bone mass” (or “osteopenia”) • 
T-score -2.5 or below is osteoporosis • 
However, there is an increasing trend to use risk factors with or without BMD to predict 
future fracture risk, for example the FRAX-score. When the risk is high enough, therapy 
is sometimes initiated even without performing a DXA to measure BMD [34, 35]. The 
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most common risk factors for osteoporotic fractures are: age, sex, immobility, previous 
fractures, familial fractures (especially a history of hip fractures of mothers), low body 
mass index, use of corticosteroids and smoking, low BMD and RA [34, 35].
Osteoporosis without any clear cause, apart from aging, is called primary 
osteoporosis. Several diseases and drugs may lead to an increased fragility of bone: 
i.e. rheumatoid arthritis, systemic lupus, ankylosing spondylitis, hyperthyroidism, 
hyperparathyroidism, celiac disease, corticosteroids and thyroid hormone, which is 
called secondary osteoporosis.
Bisphosphonates are the most frequently used drugs for treatment and prevention 
of osteoporosis. These drugs are synthetic analogues of pyrophosphate and inhibit 
osteoclast-mediated bone resorption. Bisphosphonates have demonstrated an increase 
of BMD and a decrease of vertebral and non-vertebral fracture risks in men and 
postmenopausal women [36, 37]. 
Rheumatoid arthritis and osteoporosis
Joint destruction is one of the hallmarks of rheumatoid arthritis. Joint destruction is 
a local loss of bones forming the joints, which can be divided into two types: peri-
articular osteoporosis and joint erosions. Besides this local bone loss, there is also an 
increased generalized loss of bone in RA. Several studies have shown that patients 
with rheumatoid arthritis have a lower bone mass and a higher rate of bone loss than 
general population [38-41]. This low bone mass is associated with several disease 
characteristics such as disease duration, joint destruction, use of corticosteroids and 
disease activity (inflammation) [42-44], causing not only a decrease of bone mass but 
also a decrease of bone strength [45]. Consequently, there is also an increased rate of 
vertebral and non-vertebral fractures in patients with RA [46, 47].
In several studies there is a clear association between localized bone loss in RA and 
generalized loss of bone, indicating a common pathway for this loss of bone [48, 49]. 
There is not only this epidemiological evidence for an association between generalized 
and localized bone loss, but it also has a pathological substrate. In bone metabolism 
there is usually an equilibrium between bone formation (osteoblasts) and bone 
resorption (osteoclasts). This equilibrium is disturbed by the inflammation in RA. 
Receptor Activator of NfKB (RANK) and osteopogesterin (OPG) system provide 
an aetiological explanation. RANK-ligand (RANKL) is an activator of osteoclast 
differentiation and activation, expressed on osteoblasts, fibroblasts and activated 
T-cells. OPG is the natural occurring decoy receptor for RANKL. Inflammatory 
cytokines, such as TNF and IL-1, involved in the inflammatory process of RA can 
induce expression of RANKL and thereby an increase of bone resorption [50, 51]. 
12
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Another pathway involved in bone metabolism that is influenced by inflammation is the 
wingless (Wnt) signaling pathway. Wnt, a glycoprotein, is amongst others responsible 
for the differentiation of mesenchymal progenitors into osteoblasts. This process 
is inhibited by Dickkopf-1 (DKK-1) and sclerostin binding with the Wnt receptor 
complex on pre-osteoblasts, and it prohibits the binding of Wnt with its receptor [51, 
52] (Figure 1). At least DKK-1 seems to be increased by TNF and it is associated with 
joint damage in RA patients [54]. Blocking DKK1 and sclerostin in mouse models of 
arthritis also prevents the formation of joint erosions and generalized bone loss [55, 
56]. To conclude, there are mechanisms for inflammatory induced, increased bone 
resorption and decreased bone formation in RA.
OUTLINE OF THE THESIS
This thesis is divided into two parts. In the first part data are presented on our 
investigations into generalized bone loss and local bone loss in rheumatoid arthritis. 
In the second part data are shown of several investigations we undertook in our cohort 
of RA patients treated with infliximab (a TNF- blocker).
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Figure 1 Wnt signalling pathway.53
Part 1
In chapter 2 and 3 findings of our studies about the association between rheumatoid 
arthritis and osteoporosis are reported. In chapter 2 short-term and long-term data 
on the effect of infliximab on markers of bone metabolism BMD in RA patients are 
shown. Chapter 3 deals with data from the 5 year follow-up study of the OSTRA 
cohort, a cohort of female postmenopausal RA patients with an established disease. 
The OSTRA-group is an international collaboration between OSlo (Norway), TRuro 
(United Kingdom) and Amsterdam (the Netherlands) studying bone (metabolism) in 
patients with inflammatory diseases. Data on fractures (vertebral and non-vertebral) 
and BMD of the spine, hip and hands are reported.
Part 2
In chapter 4, 5, 6 and 7 data are shown about our cohort of RA patients treated 
with infliximab (anti-TNF), which we used for our study on several other aspects 
of rheumatoid arthritis and anti-TNF treatment. This cohort was established in 
Amsterdam in 2001: all RA patients treated with infliximab in the Jan van Breemen 
Institute, Slotervaartziekenhuis and VU University medical center were included and 
followed for several years or until termination of infliximab treatment.
There is mounting evidence of increased cardiovascular co-morbidity in RA. In 
chapter 4 the effects are studied of inflammation and anti-TNF treatment on lipid 
levels. The effects of anti-TNF treatment on IgM-rheumatoid factor and anti-CCP 
levels are reported in chapter 5.
Treatment with infliximab is very effective in RA, although in several patients there 
is loss of efficacy after a number of infusions. Chapter 6 shows the effects of the 
development of antibodies against infliximab on the clinical response to infliximab. 
The powerful immune suppression by anti-TNF raises concern about the side effects, 
especially regarding the risk of infections. In chapter 7 data are presented about the 
occurrence of side effects in daily clinical practice in anti-TNF treated RA patients.
Quite a few patients with osteoporosis do not tolerate oral bisphosphonates because 
of gastro-intestinal complaints. In chapter 8, in an open randomized study, the effect 
of pamidronate intravenous infusions on BMD is compared with oral alendronate in 
patients with osteoporosis. Finally, a summary of the results and a conclusion is given 
in chapter 9.
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Chapter 2a
TO THE EDITOR
Rheumatoid arthritis (RA) is characterized by localized destruction of synovium, 
cartilage, and bone. Loss of bone in RA is not only localized in joints but is also 
generalized, and the latter (osteoporosis) is recognized as an extraarticular manifestation 
of the disease [1]. Bone loss in RA is related to disease activity, immobility and 
corticosteroid use [2]. Bone remodeling is a continuous process of bone resorption and 
bone formation. In RA, bone loss seems to be related to elevated bone resorption, while 
data on bone formation are conflicting [3-5]. Infliximab is effective in the treatment of 
RA: it causes marked reduction in disease activity and slows the radiologic progression 
of localized bone destruction [6]. Therefore, we undertook a study to determine its 
effect on markers of bone metabolism in patients with RA.
We studied consecutive patients with active RA, defined as a 28-joint Disease 
Activity Score (DAS-28) [7] of ≥3.2 who were treated with infliximab. Infliximab was 
administered by intravenous infusion at a dosage of 3 mg/kg at baseline and 2 weeks 
and 6 weeks thereafter. At each visit, data on disease activity (erythrocyte sedimentation 
rate, C-reactive protein level, disease activity rated on a visual analog scale, number 
of swollen and tender joints) and corticosteroid use were recorded. A patient was 
classified as a responder when the DAS-28 was decreased by at least 1.2 points at 6-week 
follow-up. Blood samples were collected on the morning of each infusion, and sera 
were stored immediately at -70 °C until assessment. Bone formation was measured 
by determining serum levels of osteocalcin (OC), N-propeptide of type I procollagen 
(PINP), and bone-specific alkaline phosphatase (BAP). Bone resorption was measured 
by determining serum levels of β-isomerized C-telopeptide of type I collagen (β-CTX) 
and C-propeptide of type I collagen (ICTP). All markers of bone metabolism were 
measured using commercial assays according to the instructions of the manufacturers 
(OC and β-CTX, measured with an Elecsys 2010 [Roche Diagnostics, Mannheim, 
Germany], BAP with an enzyme-linked immunosorbent assay [ELISA; Quidel, San 
Diego, CA], PINP and ICTP with a radioimmunoassay and an ELISA respectively 
[Orion Diagnostica, Helsinki, Finland]). Data on markers of bone metabolism were 
compared by paired t-test and Wilcoxon’s signed rank test when appropriate.
Sixty-eight patients were included in the study: 54 women and 14 men, with a mean 
± SD age of 55, ± 13.8 years and a median disease duration of 10 years (range <1 
year–59 years). Forty-eight patients (71%) were IgM rheumatoid factor positive (>30 
IU/ml). Sixty-one patients (90%) took methotrexate (median 15 mg/week), and 5 took 
other disease-modifying antirheumatic drugs during the study period. At baseline, 
31 patients (46%) were taking corticosteroids (prednisone [median 10 mg/day]). In 
19 of these patients the prednisone dosage remained stable during the study, whereas 
in 12 it was decreased. The mean ± SD DAS-28, 5.9 ± 1.4 at baseline, was decreased 
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significantly after infliximab treatment (4.6 ± 1.4 [p<0.001 versus baseline] at week 
2 and 4.1 ± 1.5 [p<0.001 versus baseline] at week 6). Fifty-one patients (75%) were 
classified as responders and 17 as non-responders.
OC and PINP levels were significantly increased after 2 weeks and 6 weeks compared 
with baseline (p<0.001), while BAP levels did not change significantly (Table 1). 
When bone formation was analyzed only in the patients who took prednisone at a 
stable dosage or in those who did not take prednisone during the study, we also found 
a statistically significant increase in markers of bone formation. ICTP and β-CTX 
levels showed decreases, but only the decrease in the ICTP level at 6 weeks reached 
statistical significance (p<0.001) (Table 1). In the responder group, both markers of 
bone resorption (ICTP and β-CTX) were decreased significantly at 6 weeks compared 
with baseline (p<0.05). The change in levels of bone formation markers in the responder 
group was similar to that observed in the total group. In the nonresponder group, none 
of the markers of bone metabolism showed significant change. Changes in β-CTX 
levels were slightly correlated with changes in the DAS-28 (r=0.348, p=0.05), while 
changes in the other markers of bone metabolism were not significantly correlated 
with changes in disease activity. 
Our data suggest that treatment with infliximab has a favorable effect on bone 
metabolism in patients with RA. Several studies have investigated levels of markers 
of bone metabolism in RA patients. Active RA was associated with increased levels of 
bone resorption in these studies [3, 4]. Our findings are in accordance with these data, 
since the decrease in disease activity of RA paralleled the decrease in markers of bone 
resorption. Reports on markers of bone formation are conflicting: both increased and 
decreased levels of bone formation markers in patients with RA have been reported 
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OC, osteocalcin; PINP, N-propeptide of type I procollagen; BAP, bone-specific alkaline phosphatase; ICTP, 
C-propeptide of type I collagen; β-CTX, β-isomerized C-telopeptide of type I collagen.
† p<0.001 versus baseline.
Table 1 Markers of bone metabolism in 68 rheumatoid arthritis patients at baseline and 
after 2 weeks and 6 weeks of infliximab treatment 
 Baseline Week 2 Week 6
Formation, mean ± SD    
OC, ng/ml 21.2 ± 11.4 23.0 ± 11.7† 23.9 ± 11.4†
PINP, μg/ml 43.9 ± 21.3 50.6 ± 23.7† 50.1 ± 21.1†
BAP, units/liter 22.3 ± 3.7 23.2 ± 4.8 22.7 ± 5.7
Resorption, median (interquartile range)    
ICTP, μg/ml 8.9 (7.1–12.3) 8.6 (6.8–11.6) 7.8 (6.2–10.2)†
β-CTX, ng/ml 0.32 (0.17–0.44) 0.29 (0.18–0.44) 0.29 (0.17–0.46)
[4, 5]. The observation that markers of bone formation, with the exception of BAP, 
increased during infliximab treatment was somewhat unexpected. Theoretically, the 
increase in bone formation could be the result of a decrease in the prednisone dosage 
in some patients [8]. However, in the present study this is unlikely: when we analyzed 
the patients who were not taking steroids and those who were taking steroids at a stable 
dosage during the study period, there were still significant increases in OC and PINP 
levels. Another possible explanation is that bone formation is depressed in active RA, 
as a result of disease activity. Thus, the increase in markers of bone formation might 
reflect the inhibition of suppressed bone formation in active RA. Whether long-term 
treatment with infliximab has a positive effect on bone metabolism, and subsequently 
on bone mineral density and fracture rate, will require further investigation.
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ABSTRACT
Objectives To examine whether treatment with anti-tumour necrosis factor (TNF) α 
prevents loss of bone mineral density (BMD) at the spine and hip (generalised) and 
in the hands (local) of patients with rheumatoid arthritis, and to study the changes in 
markers of bone metabolism, including receptor activator of the NFκB ligand (RANKL) 
and osteoprotegerin (OPG), during anti-TNF treatment.
Patients and methods: In total 102 patients with active rheumatoid arthritis, who 
were treated with infliximab during 1 year, were included in this open cohort study. 
The BMD of the spine and hip (dual X-ray absorptiometry) and hands dual X-ray 
radiogrammetry was measured before the start of treatment and after 1 year. Changes 
in osteocalcin formation, β-isomerised carboxy terminal telopeptide of type 1 collagen 
(β-CTx, resorption), RANKL and OPG were determined at 0, 14, 30 and 46 weeks.
Results: The BMD of the spine and hip was unchanged during treatment with 
infliximab, whereas BMD of the hand decreased significantly by 0.8% (p<0.01). The 
BMD of the hip in patients with a good European League Against Rheumatism response 
showed a favourable change compared with patients not achieving such a response. 
Serum β-CTx and RANKL were both considerably decreased compared with baseline 
at all time points. The decrease in β-Tx was associated with the decrease in Disease 
Activity Score of 28 joints and C reactive protein during the 0–14 weeks interval.
Conclusion: In patients with rheumatoid arthritis treated with infliximab, spine and 
hip bone loss is arrested, whereas metacarpal cortical hand bone loss is not stopped. 
The outcome of the study also supports a relationship between clinical response, in 
terms of reduced inflammatory activity, and changes in bone loss of the spine, hip 
and hands.
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INTRODUCTION 
Bone loss in the joints is one of the hallmarks of rheumatoid arthritis. This local 
bone loss can be divided into erosions of the joint and periarticular osteoporosis. 
Apart from this localised process, generalised bone loss (osteoporosis) is increased 
in patients with rheumatoid arthritis [1-3]. Recent literature suggests that these 
two types of bone loss are at least partly mediated through the same mechanism. A 
previous study from the Oslo-Truro-Amsterdam group showed that the Larsen Score 
for joint damage was associated with bone mineral density (BMD) of the hip and 
the occurrence of vertebral deformities in patients with rheumatoid arthritis [4, 5]. 
Other clinical studies in patients with rheumatoid arthritis found similar associations 
between osteoporosis and radiographic joint damage [6-10]. The receptor activator of 
the NFκB ligand (RANKL) and osteoprotegerin (OPG) system provides a theoretical 
background for such a common mechanism. RANKL is a membrane-bound protein 
and a key factor in the activation and differentiation of osteoclasts by binding to its 
receptor RANK on premature osteoclasts. OPG is the antagonist of RANKL and 
suppresses the differentiation and activation of osteoclasts [11, 12]. RANKL expression 
is one among the factors up regulated by several proinflammatory cytokines — that is, 
tumour necrosis factor (TNF)α and interleukin 1 (IL1) [13, 14]. Currently, the most 
effective drugs for the treatment of rheumatoid arthritis are the TNFα blocking agents 
(infliximab, etanercept and adalimumab). Randomised controlled trials have shown 
that these drugs retard radiographic joint destruction [15, 16]. This finding raises the 
question whether these agents also have the ability to prevent generalised bone loss 
in the spine and hip, and local bone loss in the hands in patients with rheumatoid 
arthritis. We aimed to address this question and to study changes in markers of bone 
metabolism, including RANKL and OPG, during such treatment. 
PATIENTS AND METHODS 
Patients
Consecutive patients with rheumatoid arthritis from four rheumatology departments, 
VU University Medical Centre (VUMC), Jan van Breemen Institute (JBI), Slotervaart 
Hospital, Amsterdam, the Netherlands, and Diakonhjemmet Hospital, Oslo, Norway, 
who were treated with infliximab for at least 1 year and had dual X-ray absorptiometry 
(DEXA) measurements at baseline and at follow-up were included. All patients fulfilled 
the American College of Rheumatology criteria for rheumatoid arthritis, had active 
disease (Disease Activity Score of 28 joints (DAS-28) 3.2), and had previously failed at 
least two disease modifying antirheumatic drugs (DMARDs), including methotrexate 
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[17, 18]. In total, 138 patients were included in the cohort, but 36 patients dropped out 
in the first year of treatment: 28 because of non-response (78%), 6 because of side effects 
(16%) and 2 patients (6%) who died owing to infliximab-unrelated events. Thus, the 
data from 102 patients were eligible for analyses (Table 1). The baseline characteristics 
of the dropout patients were comparable to those of the patients included in the study 
(data not shown).
Methods 
Infusions with infliximab were given at 0, 2, 6 and 14 weeks, and after that at an interval 
of 8 weeks. Infliximab was given intravenously at a starting dose of 3 mg/kg. The dose of 
infliximab could be increased to 7.5 mg/kg in patients who showed inadequate response, 
according to clinical judgement. A dose increment occurred in 21 patients.
Demographics and disease-related data
The demographic data collected at baseline were recorded from medical history and 
patients’ medical records. The following variables were collected: age, sex, disease 
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Table 1 Baseline characteristics of the patients with rheumatoid arthritis (N=102) 
Demography  
Age (years), mean (SD) 53 (13)
Sex, female, n (%) 84 (82)
Disease duration years, median (range) 8 (1–49)
Erosive disease, n (%) 84 (82)
IgM-RF positive, n (%) 75 (74)
Disease activity  
DAS-28, mean (SD) 5.4 (1.2)
ESR (mm/h), mean (SD) 32 (23)
CRP (mg/l), median (range) 14 (1–174)
Drugs  
Methotrexate, n (%) 98 (96)
Prednisone, n (%) 46 (45)
Anti-osteoporotic drugs, n (%) 26 (26)
BMD  
Vertebral spine (g/cm2), mean (SD), n=102 0.993 (0.19)
t-score, mean (SD) -0.82 (1.6)
z-score, mean (SD) -0.09 (1.5)
Total hip (g/cm2), mean (SD), n=89 0.830 (0.14)
t-score, mean (SD) -1.02 (1.2)
z-score, mean (SD) -0.51 (1.2)
Hand, mean (SD), n=53 0.497 (0.98)
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duration, presence or absence of bony erosions, serum rheumatoid factor status 
(positive if immunoglobulin-rheumatoid factor >30 U/l), current and previous use 
of DMARDs, anti-osteoporotic drugs and corticosteroids. 
Disease activity
The patients were assessed at each visit with core measures of disease activity, and the 
DAS-28 score was computed. The European League Against Rheumatism (EULAR) 
response criteria were applied to define response [17].
BMD of hip and spine
BMD was measured before and after 1 year of infliximab treatment using (DEXA). A 
total of 102 patients had a DEXA measurement of the spine, and in 89 patients DEXA 
measurements of the hip were available. The DEXA machines used were Hologic 
4500 (Hologic, Waltham, Massachusetts, USA) in the Slotervaart hospital and the 
VUMC, a Lunar Expert (Lunar, Madison, Wisconsin, USA) at the Diakonhjemmet 
Hospital, and a Lunar DPX (Lunar) at the JBI. The same DEXA machine used at 
baseline was used for follow-up measurement for each patient. The coefficients 
of variation, measured with a local spine phantom for the different centres, were 
acceptable and comparable: the VUMC 0.56%, Slotervaart Hospital 0.48%, JBI 0.4% 
and Diakonhjemmet Hospital 0.8%. The BMD data of spine and hip (g/cm2) and t- 
and z-scores were determined using the local reference population provided by the 
manufacturer of the DEXA machine.
BMD of the hand
BMDs of the hand at baseline and after 1 year were measured on plain radiographs 
of the left and right hand (anteroposterior view) using digital X-ray radiogrammetry 
(DXR; Pronosco X posure system, system 2.0, Sectra, Linkaping, Sweden). This method 
measures cortical thickness from regions of interest at the centre of the second, third 
and fourth metacarpals, and a mean BMD surrogate is calculated. The theoretical 
background for this method has been fully described [19, 20]. The coefficient of 
variation for this method was 0.25% [21]. The Pronosco DXR system we used is 
validated only for evaluation of conventional radiographs. Fifty three patients had 
conventional radiographs available for evaluation. The baseline characteristics and 
change in disease activity of the subgroup of patients with hand radiographs were 
comparable to those of the whole group. The patient data for BMD of the hand (g/
cm2) are given as the mean of the right and left hand.
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Markers of bone metabolism
In a total of 72 patients serum samples were available for evaluation. These patients also 
had baseline characteristics and change in disease activity similar to that of the entire 
patient group. Serum was collected in the morning (non-fasting) before each infusion 
and stored immediately at -20 °C or lower until analyses. Markers of bone metabolism 
were measured at 0, 14, 28 and 46 weeks. Bone formation was measured by osteocalcin, 
and bone resorption was determined by β-isomerised carboxy terminal telopeptide 
of type 1 collagen (β-CTx) using commercial assays according to the instructions of 
the manufacturer (Roche Diagnostics, Elecsys 2010, Mannheim, Germany). Levels 
of osteoclast regulating proteins, including the soluble RANKL and OPG, were 
determined in serum using an ELISA from Immun diagnostik (Bensheim, Germany). 
All assays had an intra-assay and interassay coefficient of variation of <5%.
Statistical analysis
Paired t-tests and Wilcoxon rank tests were used to examine longitudinal changes in 
BMD and markers of bone metabolism, where appropriate. Subgroup analyses were 
carried out to investigate differences in change in BMD of the spine, the hip and the 
hand in different groups. Patients were categorised according to achieved EULAR 
response, use of prednisolone and bisphosphonate, and presence of radiographic 
erosions. Changes in BMD between these subgroups were analysed using an 
independent Student’s t-test or Mann-Whitney U test as necessary.
Associations between changes in BMD and changes in disease activity and bone 
markers were also examined in a multivariate linear regression model adjusted for age, 
sex, disease duration, erosive disease, prednisolone and bisphosphonate use.
Similar regression analyses were carried out with bone markers as the dependent 
variable and disease activity as independent variable. The changes in markers of 
bone metabolism and the association with disease activity markers were investigated 
separately between the different time points: 0–14, 0–30 and 0–46 weeks.
All data were analysed using the SPSS V.11.1 software package. A value of p<0.05 was 
considered to be significant.
RESULTS
The mean (standard deviation (SD)) disease activity measured by DAS-28 decreased 
from 5.5 (1.2) at baseline to 3.8 (1.4) after 14 weeks, 3.6 (1.3) after 30 weeks and 3.5 
(1.4) after 46 weeks (p<0.001 at all time points compared with baseline). In all, 40 
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patients had a good response, 43 patients a moderate response and 19 patients a non-
response at 46 weeks as defined by the EULAR response criteria.
Bone mineral density
One fifth of the 102 patients had osteoporosis (t-score <-2.5 at either spine or hip), and 
osteopenia (t-score <-1.5 but >-2.5 at either spine or hip) was present in almost half 
(47%) of the patients. A considerably lower BMD of the spine and hip was observed 
at baseline in patients with erosive disease than in patients with non-erosive disease 
(data not shown).
BMD of the vertebral spine and hip remained unchanged during treatment with 
infliximab. In contrast, BMD of the hand decreased significantly by 0.004 g/cm2 (-0.8%) 
during the year (p<0.05; Table 2). The mean z scores of the spine and hip showed an 
increasing trend: 0.039 and 0.023, respectively (p=0.334 and 0.376).
Using the smallest detectable difference for each measurement, we calculated the 
number of patients who lost, gained and maintained BMD for each site (Table 3).
There was no significant difference in change in BMD between the patients from 
different centres, patients with and without bone markers for evaluation, and patients 
with and without DXR measurements.
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Table 2 Mean percentage change (SD %) in the bone mineral density of the spine, hip 
and hand for all patients and for patients with (40%) and without (60%) good European 
League Against Rheumatism (EULAR) response
* p<0.001 versus those without good response.
 
 Good EULAR response
All No Yes
Vertebral-spine (n=102) 0.20 (5.1) -0.57 (5.0) 0.74 (5.3)
Total hip (n=89) -0.20 (3.6) -0.68 (3.8) 0.77 (3.4)*
Hand (n=53) -0.82 (2.4) -1.2 (2.6) -0.63 (2.3)
Table 3 Number of patients losing, maintaining and gaining bone mineral density during 
1-year treatment with infliximab
Gain n (%) Maintain, n (%) Lose, n (%)
Vertebral-spine (n=102) 32 (31) 39 (38) 31 (30)
Total hip (n=89) 14 (16) 61 (68) 15 (16)
Hand (n=53) 6 (11) 22 (42) 25 (47)
Markers of bone metabolism
The bone resorption marker, β-CTx (ng/ml), decreased considerably from 0 to 14 weeks 
and remained markedly decreased during the rest of the year (Figure 1). The marker for 
bone formation, osteocalcin (ng/ml), was appreciably increased at 14 weeks compared 
with baseline, but not at 30 and 46 weeks (Figure 1B ). RANKL (pmol/ml) decreased 
markedly during the year whereas OPG (pmol/ml) did not change markedly. This 
resulted in a favourable change in the RANKL/OPG ratio.
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Figure 1  (A–E) Changes in median β-isomerised carboxy terminal telopeptide of type 1 
collagen (β-CTx, resorption), osteocalcin formation, receptor activator of the NFκB ligand 
(RANKL), osteoprotegerin (OPG) and RANKL/OPG ratio during treatment with infliximab. 
* p<0.05 versus baseline.
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Associations between changes in disease activity, BMD and bone 
markers
The change in the BMD of the spine, hip and hand was numerically larger in patients 
without good EULAR response than in patients achieving a good response (a decrease 
in DAS>1.2 resulting in a DAS<3.2; Table 2). This difference was significant between 
these two groups at the hip.
The BMD changed non-significantly in both the prednisone users and the non 
prednisone users, by +0.2% and -0.04% at the spine, by -0.2% and -0.28% at the hip, 
and by -0.9% and -0.7% at the hand, respectively. No significant difference was found 
in change in BMD between the prednisone and non prednisone users.
Subgroup analysis for bisphosphonate use also did not show any difference in the 
change in BMD between the users and non-users.
In the multivariate linear regression model investigating the influence of disease 
activity on markers of bone metabolism, we found a relationship between the change 
in β-CTx and the change in DAS-28 and C reactive protein during the 0–14 week 
time interval (C=0.302, B=0.015, p<0.05 and C=0.315, B=0.002, p<0.05, respectively). 
At the other time intervals there was no significant relationship between β-CTx and 
markers of disease activity. OPG showed a weak inverse association with the change 
in DAS-28 at all the time intervals (data not shown). No significant association was 
found between changes in disease activity and levels of osteocalcin or RANKL at any 
of the time intervals.
DISCUSSION
The main findings of this study were that 1 year treatment with infliximab arrests 
generalised bone loss in patients with rheumatoid arthritis, without stopping the 
localised bone loss at the hands. An increased generalised bone loss is usually found 
in observational studies of patients with rheumatoid arthritis owing to the negative 
effects of rheumatoid arthritis on bone loss (disease activity and immobilisation) 
[2, 3]. We compared our results with those of historical control groups from earlier 
studies of patients with established rheumatoid arthritis, which have shown a bone 
loss of up to 0.7% at the spine and -1.1% at the hip during 1 year, when treated with 
conventional DMARDs [22-24]. The generalised annual bone loss in patients with early 
rheumatoid arthritis is even larger: -4.2% at the spine and -2.1% at the hip [25, 26]. Our 
study population consisted of patients with early and established rheumatoid arthritis, 
and 27 patients had disease duration <3 years, emphasising the favourable changes 
in BMD we found in our study. The z-scores in our patients showed an increasing 
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trend, supporting the observation that treatment with infliximab arrests loss of BMD 
in patients with rheumatoid arthritis. Comparison of our data with the data derived 
from historical control groups having methodological limitations clearly shows that 
bone loss is far less in patients treated with an active regimen of TNFα blockers. In 
contrast with the effects on BMD of the spine and the hip, BMD of the hand measured 
by DXR decreased considerably. There is a lack of data on hand BMD measured by 
DXR in patients with established rheumatoid arthritis treated with conventional 
DMARDs. Therefore we do not know how this bone loss at the hand compares 
with other cohorts of patients with rheumatoid arthritis. A comparable finding was 
observed in a small pilot study comparing patients with rheumatoid arthritis (n=10 
in each group) treated with infliximab or methotrexate. In this study, the bone loss 
was fully arrested in the infliximab group at the spine and hip but not at the hands 
[27]. In the present study, patients with a good EULAR response had increased BMD 
of the spine and hip. However, bone loss at the hand was also not fully arrested in 
the good responder group. The bone loss at the hands may suggest that the negative 
effects of patients with rheumatoid arthritis are not fully blocked. This hypothesis of 
a suboptimal anti-inflammatory control at the hands is supported by findings from a 
recently published double-blind randomised controlled trial showing that the rate of 
hand bone loss measured by DXR was considerably lower in patients with rheumatoid 
arthritis treated with prednisolone than in patients treated with placebo, but dropped 
markedly over time in both treatment groups [21]. In the large randomised controlled 
trial of patients with rheumatoid arthritis treated with infliximab, radiological damage 
was also not fully arrested, especially in patients treated with infliximab 3 mg/kg. 
Radiological joint damage was, however, fully arrested in the high dose infliximab 
group (10 mg/kg) [16, 28]. Thus, despite infliximab having a favourable effect on 
the disease activity in most patients, it might not fully block the radiological damage 
and bone loss at the hands at a dose of 3 mg/kg. Bone resorption, as depicted by 
β-CTx, decreased during the treatment with infliximab (as expected), whereas bone 
formation (assessed by osteocalcin) increased. We found that the change in disease 
activity (DAS-28 and C reactive protein) between 0 and 14 weeks was independently 
related to the change in bone resorption marker β-CTx between 0 and 14 weeks. This 
supports the view that infliximab reduces disease activity and thereby prevents bone 
loss. The change in osteocalcin was not observed in patients not using prednisone, 
and was more pronounced in the patients with rheumatoid arthritis using prednisone 
(data not shown). Prednisone is a well-known suppressor of bone formation [29]. 
Hence, the increase in osteocalcin is probably induced by a decrease in prednisone 
dosage during the study, because of the good clinical response to infliximab. The 
osteoclast activating protein RANKL showed a linear decrease during the treatment 
with infliximab. This resulted in a favourable change in the RANKL/OPG ratio. In the 
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Combinatie Therapie Bij Reumatoïde Artritis study (COBRA), an intervention study 
in patients with early rheumatoid arthritis, the RANKL/OPG ratio at baseline was a 
good predictor of radiological joint damage [30]. Overall, the changes in bone markers 
during 1 year with infliximab treatment support the bonesparing effect of infliximab 
observed in our study. In summary, our study shows that in patients with rheumatoid 
arthritis treated with infliximab, loss of BMD at the hip and spine is arrested, but not 
that at the hands. The fact that bone loss was arrested at the hip and the spine seems 
to be to a large extent due to a decrease in disease activity.
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Chapter 3a
ABSTRACT
Introduction: To investigate the incidence of vertebral and non-vertebral fractures over 
a 5-year period in a cohort of postmenopausal patients with established rheumatoid 
arthritis (RA).
Methods: 150 female patients with established RA were included into the OSTRA 
cohort. The cohort was assessed at baseline and at 5 years for incident vertebral and 
non-vertebral fractures. Spinal X-rays were taken at baseline and at follow-up and 
scored using the semi-quantitative method according to Genant.
Results: At 5 years, 102 patients (68%) were examined and included in the present 
analysis. At baseline, the mean age was 61 years, disease duration 17 years, body mass 
index 25.5 kg/m2 and 65% of the patients were rheumatoid factor positive. Fifteen 
percent were treated with bisphosphonates, 25% received calcium supplementation 
and 20% vitamin-D supplementation at baseline. During 5-year follow-up a total of 16 
patients out of 102 patients (16%) had a new non-vertebral fracture (annual incidence 
of 3.2 (95% CI 1.8–5.5) per 100 patients/year). In 18 patients out of 97 patients (19%), 
new vertebral fractures were identified on spinal X-ray (annual incidence of 3.7 (95% 
CI 2.2–5.8) per 100 patients/year).
Conclusions: We found a high incidence of vertebral and non-vertebral fractures in a 
cohort of women with established RA compared to population based studies.
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INTRODUCTION 
Osteoporosis is a well known extra-articular feature of rheumatoid arthritis (RA). Bone 
mineral density (BMD) is decreased in patients with RA [1, 2]. The clinical endpoint 
of osteoporosis, fractures are also more prevalent in RA patients compared to the 
general population [3-5]. Reasons for this decreased BMD and increased prevalence 
of fractures in RA include among others inflammation, reduced physical activity 
and corticosteroid use [2]. Almost all data regarding osteoporosis in RA is generated 
from cross sectional studies. Longitudinal studies are scarce, especially studies with 
a focus on fractures. Recently, van Staa et al. reported, that in a large case-control 
study the risk of fractures was about 1.5 times higher in RA patients than in healthy 
controls [4]. In this study only clinical fractures were assessed and spinal X-rays were 
not performed routinely to identify asymptomatic vertebral fractures. However these 
asymptomatic fractures are also associated with an increased risk of new fractures and 
with an increased morbidity [6, 7].
The OSTRA-group (OSlo, TRuro, Amsterdam) is an international collaboration 
investigating osteoporosis in RA. Five years ago the OSTRA-group performed a study 
in postmenopausal patients with RA and found that radiological joint damage (total 
Larsen-score) was associated with a low BMD and vertebral fractures [8].
To further clarify the association between RA and osteoporosis we performed a 5-year 
follow-up assessment of this cohort. The main objective of this 5-year follow-up study 
was to evaluate the incidence of vertebral and non-vertebral fractures in female post-
menopausal RA patients. 
PATIENTS AND METHODS 
Patients
All 150 patients from the original study were eligible to participate in the follow-up 
study. The inclusion and exclusion criteria for the baseline study have previously been 
described in detail [8]. In short, in each of 3 centers, general rheumatology clinics in 
Oslo (Norway), Truro (UK), and Amsterdam (the Netherlands), 50 female patients 
were consecutively enrolled. The patients included were 50–70 years old and fulfilled 
the American College of Rheumatology (formerly American Rheumatism Association) 
1987 revised classification criteria for RA. The disease duration of all patients was 5 or 
more years [9]. In total, 102 patients of the original cohort consented to a follow-up 
assessment (33 from Oslo, 34 from Truro, and 35 from Amsterdam). The main reasons 
for not participating in the follow-up study were: 15 moved away from the hospital 
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area, 5 suffered from severe co-morbidity, 8 had died and 20 did not participate for 
unknown reasons or could not be contacted. The baseline characteristics of the 102 
patients, who had a follow-up measurement did not differ form the characteristics of 
all the 150 patients at baseline and of those patients (n=42) that dropped out ((lowest 
p=0.282) data not shown).
Demographics and medical history 
Data at follow-up were collected from interviews, clinical examination, questionnaires 
and patient’s medical records and included:, height, weight, calcium intake, history of 
falls (number of falls during the last year and cause) and fractures (anatomical site and 
cause), current and previous use of anti-osteoporotic (anti resorptive therapy (ART) and 
hormone replacement therapy (HRT)) and disease-modifying anti-rheumatic drugs 
(DMARDs) and history of corticosteroid use (previous and current use, cumulative 
amount over the past 5 years, use of ≥7.5 mg for >6 months, and number of months on 
corticosteroids). Physical disability was assessed by means of the Health Assessment 
Questionnaire (HAQ; 20 items, score range 0–3, with higher scores indicating worse 
disability) [10]. 
Disease activity
Measures of RA disease activity were assessed with visual analogue scales (0–100 
mm) of pain and patient’s global disease activity; 28 tender and swollen joint counts, 
and acute phase reactants (the erythrocyte sedimentation rate [ESR; mm/hour] and 
C-reactive protein [CRP; mg/L], both measured with standardized local measurement 
techniques). The modified 28 joints disease activity score (DAS-28) was calculated 
according to published guidelines [11]. Joint scores were performed by experienced 
rheumatology nurses in Oslo and Truro and in Amsterdam by a physician (MV). The 
mean ESR and CRP were calculated based on all available measurements during the 
5-year follow-up.
Fractures
Non-vertebral
Non-vertebral fractures and their cause were assessed at 5-year follow-up by interview 
and were validated by checking available data (radiology reports and chart review). 
Low-energy traumatic fractures (i.e. a fall from standing height) were regarded as 
osteoporotic fractures. 
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Vertebral 
All spinal X-rays were taken according to local protocol, the same protocol was used 
at baseline and follow-up. Lateral radiographs of the spine were scored according to 
the semi-quantitative method described by Genant et al. [12]. Scoring was performed 
individually by 2 trained observers (MV and WL) and consensus both at baseline 
and follow-up was obtained in cases of discrepancies between both observers. 
Follow-up radiographs were scored blinded for the baseline image, and the results 
were subsequently compared to the baseline X-rays and scores to see if new vertebral 
fractures were detected. A fracture was scored as an incident vertebral fracture if it 
was not present at baseline or if there was a significant increase in loss of height (more 
than 20%) in a vertebra which was already fractures at baseline.
Ethics
The study protocol was approved by the local medical ethical committees of the 3 
centers and all patients gave written informed consent. 
Statistical analysis
Patients with incident fractures (vertebral or non-vertebral fractures) were compared to 
those not having a new fracture with regard to demographic variables, clinical variables 
and BMD using 2-sided t-tests for continuous variables and chi-square tests for counts. 
The incidence of patients with fractures was expressed per 100 patients/year with 95% 
confidence intervals (CI). Possible predictors of incident vertebral and non-vertebral 
fractures were subsequently examined in a multivariate logistic regression analysis. 
The criteria for entering independent variables in the logistic regression analysis was 
a p<0.2 in the univariate analysis and a supposed clinical relevance for the dependent 
variable. We were able to build a prediction model with only significant covariates by 
using backward stepwise elimination of the least significant covariate. All statistical 
analyses were performed using the SPSS (Chicago, IL), version 15.0. 
RESULTS
Patient characteristics
The clinical characteristics of the 102 patients included in this study are presented in 
Table 1. At baseline the patients had a mean (SD) age of 61 (6) years with a median 
(range) disease duration of 17 (6–25) years, 83% of the patients had erosive disease 
and 65% patients were rheumatoid factor positive.
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Table 1 Characteristics of the 102 patients with RA included in the 5-year follow-up
* used for at least 1 month during the 5-year follow-up period.
** using at follow-up.
*** t-scores at either total-hip and/or vertebral spine.
na, non applicable.
Baseline Follow-up
Age [years] Mean (SD) 61 (6) na
Disease duration [years] Median (range) 17 (6–25) na
IgM-RF [positive (>25 U/ml)] n (%) 67 (65) 67 (65)
Joint erosions present [patients] n (%) 85 (83) 85 (83)
BMI [kg/m2] Mean (SD) 25.5 (5) 26.0 (5)
HAQ Mean (SD) 1.48 (0.62) 1.59 (0.89)
Corticosteroids
Ever use n (%) 65 (64) na
Use [during follow-up] n (%) na 58 (57) *
Months used [during follow-up] Mean (SD) na 43.8 (25.4)
>7.5mg for >6 months [during follow-up] n (%0 na 18 (32)
Anti-osteoporosis medication
Anti-resorptive treatment n (%) 15 (15) 31 (31)**
Hormone replacement treatment n (%) 31 (30) 0 (0)**
Calcium supplementation n (%) 41 (40) 51 (50)**
Vitamin-D supplementation n (%) 28 (27) 43 (42)**
Vitamin-D and calcium supplementation n (%) 25 (24) 40 (39)
DMARD treatment [during follow-up]
Methotrexate n (%) na 66 (65)*
Duration [months] Mean (SD) na 49.2 (21.7)
Sulfasalazine n (%) na 28 (27)*
Duration [months] Mean (SD) na 40.3 (25.2)
TNF-inhibitors n (%) na 20 (20)*
Duration [months] Mean (SD) na 18.2 (11.3)
Other n (%) na 44 (43)*
Disease activity   
DAS-28 Mean (SD) 5.4 (1.3) 3.6 (1.2)
ESR [mm/hr] Median (range) 27 (2–85) 18 (2–93)
CRP [mg/L] Median (range) 11 (0–175) 5 (9–72)
Mean ESR [mm/hr] Mean (SD) na 20.9 (11.8)
Mean CRP [mg/L] Mean (SD) na 12.6 (10.9)
Osteoporosis/Osteopenia***
Osteoporosis [t-score <-2.5] n (%) 36 (35) na
Osteopenia [t-score <-1.5 and >-2.5] n (%) 26 (26) na
Fractures 
Vertebral [Genant] n (%) 15 (25) 32 (33)
Non-vertebral n (%) 24 (24) 35 (35)
The characteristics of the patients during follow-up are shown in Table 1. During 
follow-up, 58 (57%) patients used corticosteroids for a mean (SD) duration of 43.8 
(25.4) months. ART was used by 15% of the patients at baseline and during follow-
up an additional 16 patients (16%) started with ART. Calcium and vitamin-D 
supplementation were ever used by 50% and 42%, respectively for some time during the 
follow-up period. HRT was used by 31 (30%) patients at baseline, but was discontinued 
by all patients by the end of the study.
Incident non-vertebral fractures
A total of 18 patients reported 22 fractures. Two patients had fractures due to high-
energy trauma (traffic and skiing accident). Thus, 16 (16%) patients had 17 osteoporotic 
fractures. Fractures were reported at the following anatomical sites: Upper-arm (n=3), 
wrist (n=4), hip (n=3), upper-leg (n=2), ankle (n=2), ribs (n=2) and pubic bone (n=1). 
The annual incidence of patients with non-vertebral fractures in our study was 3.2 
(95% CI 1.8–5.5) per 100 patients/year.
Incident vertebral fractures
A total of 97 patients had lateral spine X-rays available for evaluation. In a total of 
18 (19%) patients 22 new vertebral fractures were identified. All incident fractures 
occurred in vertebrae which were normal at baseline. Three patients suffered more 
than one fracture. Most fractures as expected were identified in the mid-thoracic and 
thoraco-lumbar regions (Figure 1). Fifteen of the 18 patients (83%) had at least a new 
grade 2 vertebral fracture. The annual incidence rate for a new morphometric vertebral 
fracture was 3.7 (95% CI 2.2–5.8) per 100 patients/year. 
In total 32 (32%) patients had either a new vertebral or a new non-vertebral fracture.
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Figure 1 Distribution of new vertebral fractures.
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Differences in patients with and without vertebral and non-vertebral 
fractures
On average patients with a new non-vertebral fracture had a lower BMD at baseline 
compared to patients without a new non-vertebral fracture. This was significant 
only for the baseline BMD at the hip (p<0.05). In the group of patients with a new 
non-vertebral fracture more patients used ART than in the group without a new non-
vertebral fracture (62% versus 24%, p<0.05). 
When comparing patients with and without incident vertebral fractures, there were 
significantly more patients using corticosteroids (78% versus 54%) in the patients 
with a new vertebral fracture during follow-up (p<0.05). Patients with new vertebral 
fractures had also suffered significantly more non-vertebral fractures at baseline 
(p<0.05), but seemed to have less vertebral fractures at baseline (p=0.067). There was 
also a trend for a higher disease activity (mean CRP during follow-up and DAS-28 at 
baseline) in the patients with a new vertebral fracture compared to patients without 
a new vertebral fracture (Table 2).
Of the patients who were osteopenic at baseline 7 (19%) sustained a new vertebral 
fracture and 6 (17%) a new non-vertebral fracture during follow-up. In the group of 
osteoporosis patients there were 7 (27%) new vertebral and 7 (27%) new non-vertebral 
fractures during follow-up.
Possible risk factors for incident fractures
In the multivariate logistic analysis, we identified BMD at the total-hip as an 
independent predictor for incident non-vertebral fractures. BMD of the spine, ever 
steroid use, vertebral fractures and non-vertebral fractures at baseline were entered into 
the model, but were eliminated as not significant (Table 3). Non-vertebral fractures at 
baseline were an independent predictor of new vertebral fractures. BMD of the spine, 
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Table 3 Multivariate analyses of incident fractures
 B OR (95%CI) p
Non-vertebral fractures
BMD total-hip [(1,0 g/cm2] -5.6 0.003 (0.001–0.42) 0.019
Constant 2.8 16.1 0.133
 Vertebral fractures
Non-vertebral fracture at baseline 1.21 3.4 (1.3–9.6) 0.029
Constant 0.6 1.8 0.54
mean CRP over the follow-up period, DAS-28 at baseline and ever steroid use were 
entered into the model but were eliminated (Table 3). All regression models were 
corrected for centre.
DISCUSSION
In this 5-year follow-up study of postmenopausal women with established RA, we 
found a high incidence of vertebral and non-vertebral fractures. Baseline non-vertebral 
fractures were an independent predictor of new vertebral fractures and new non-
vertebral fractures were independently predicted by baseline BMD at the hip. This is 
the first study to study incident non-vertebral fractures and morphometric vertebral 
fractures in RA in a single study. These data are also unique because of the duration 
of follow-up (5 years).
In total, 19% of the patients had a new vertebral fracture during the 5-year follow-
up, corresponding to an annual incidence of 3.7/100 patients/year. Because this is an 
observational study, we have no data from a control group to compare this annual 
incidence to. Comparison with other historical cohorts is possible. In the EPOS study, a 
study of fractures in the general population of 50 years and older, the annual incidence 
rate of morphometric vertebral fractures in females was 1.07/100 patient years [13]. 
Mean age (63 years) for these patients is comparable to our study. In another study 
by Nevitt et al. the annual incidence of morphometric fractures was 0.8/100 patient 
years. This study assessed fractures in subjects 65 years and older from the general 
population [14]. Although comparisons between studies should be considered with 
caution, these studies give a clear indication of the high incidence rate of vertebral 
fractures in our study. The vertebral fractures we found were also predominantly 
moderate and severe fractures (grades II and III). There are 2 studies which performed 
a longitudinal study on radiological detected vertebral fractures. Ørstavik et al. found 
6.7 incident deformities per 100 patient years in a group of 255 female RA patients 
(mean age 54.3 years) during a mean follow-up of 2.3 years [15]. This study however 
did not use vertebral spine-X-rays but morphometric X-ray absorptiometry, this 
different technique may explain the higher incidence rate of vertebral fractures in 
this otherwise comparable study. In the other study, Katsumitsu et al. [16] found 
new vertebral fractures in 19 (16%) patients out 112 patients followed for 4 year. This 
percentage is comparable to the percentage of vertebral fractures found in our study 
during 5 years (19%). Unfortunately no data is given on the mean disease duration 
and mean age of the included RA patients.
In our study we also found a high frequency of non-vertebral fractures. When 
comparing our annual incidence of 3.1/100 patient years with the incidence from the 
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female population in the EPOS study 1.9/100 patient years, it is considerably higher. 
The EPOS is a study investigating limb fractures in man and women aged 50 tot 79 
years [17]. Finigan et al. also found an incidence 1.9 of new vertebral fractures per 100 
patient years in a 10 year follow-up population based study. Three hundred seventy-
six female patients were included into this study with an age (64.6 years) at baseline 
which is comparable to our cohort [18]. Few studies have investigated the incidence 
of clinical fractures in RA patients. In a large database study by van Staa et al., they 
identified an increased risk of fractures of 1.5 for all fractures in RA patients compared 
to healthy controls [4]. This study included all clinical fractures, also including clinical 
vertebral fractures. Nampei et al. found in a cohort of 209 RA patients (86% female, 
mean age 60 years) an incidence of patients with new fractures of 11.5/100 patient 
years [19]. This is a very high incidence, but this study investigated all patients with 
pain suspicious of a fracture very thoroughly (including MRI) for fractures, which 
could very well explain the high incidence of fractures in this study.
In our study we found few risk factors for new fractures. Our study only revealed 
well known risk factors for new vertebral fractures and new non-vertebral fractures, 
respectively baseline non-vertebral fractures and BMD of the hip at baseline. We did 
not find any specific RA related factors to be predictors for new fractures. Mean CRP 
and baseline DAS-28 showed a trend to be increased in patients with a new vertebral 
fracture (Table 3), but were not independent predictors of future vertebral fractures. 
Our study has several limitations. We performed measurements at baseline and 
at follow-up at 5 years. This is a quite long period and measurements like DAS-28 
at baseline and follow-up will probably not properly reflect the fluctuation of the 
disease activity during that period. This could explain why we found no associations 
between fractures and disease activity. Another reason for not finding an association 
could be that joint scores were performed by different investigators, which can cause 
some variability in measurements. However we also did not find an association with 
objective disease activity measures like CRP and ESR. Finally, our studied population 
might also be too small to find risk factors in rheumatoid arthritis for a multifactorial 
disease like osteoporotic fractures. Another limitation of having only measurements 
at baseline and 5 years is, that we were not able to properly investigate the relationship 
between timing of the use of anti-resorptive treatment and new fractures especially 
vertebral fractures. It could be very likely that bisphosphonates were started after a 
fracture occurred and this is probably the reason is why we did not find a protective 
effect of bisphosphonates for example.
In conclusion, in our study we found a high incidence rate of vertebral and non-
vertebral fracture rates during a follow-up of 5 years in patients with established RA 
compared to the general population.
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ABSTRACT
Objective: To investigate the changes over 5 years in BMD of the spine and hip.
Methods: 102 female RA patients form the original OSTRA-study participated in 
the follow-up study. The bone mineral density (BMD) was measured at baseline and 
after 5 years.
Results: There was a significant decrease of 5.9% (p<0.05) in total-hip BMD (g/cm2). 
At the spine (L2–L4) there were a trend toward a loss (-2.4%, p=0.059).
Conclusion: We found that even in a postmenopausal population with established, 
there was a substantial decrease in BMD of 5.9% at the hip and a 2.4% bone loss at 
the spine. 
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INTRODUCTION 
Osteoporosis occurs more frequently in patients with rheumatoid arthritis (RA) than in 
the healthy population. In cross-sectional studies, the prevalence of osteoporosis (low 
BMD) is increased in RA patients compared to the general population, while in other 
studies also elevated vertebral and non-vertebral fracture rates have been shown [1-5]. 
Longitudinal studies have linked increased bone loss in RA to disease related factors such 
as disease activity, disease duration, immobility and the use of glucocorticoids [6-9].
In a previous, multi-centre cross-sectional study of the OSTRA group we found that 
high age, low body mass index, high cumulative dose of corticosteroids were related 
to low bone mineral density (BMD) at the lumbar spine and hip and that radiological 
joint damage in RA was associated with a low BMD at the hip [9]. In the present study, 
we investigated the longitudinal changes over 5 years in BMD of the spine and hip and 
the factors influencing BMD in our cohort of postmenopausal RA patients. 
PATIENTS AND METHODS 
Patients
The 150 female RA patients from the original study were asked to participate in the 
follow-up study at 5 years [9, 10]. In total, 102 patients of the original cohort agreed 
to a follow-up assessment (35 from Oslo, 34 from Truro and 36 from Amsterdam). 
There were no significant differences in baseline characteristics between patients with 
follow-up measurements and withdrawals (data not shown).
Data 
The baseline data collection is described elsewhere [9]. At 5-year follow-up the patients 
completed questionnaires, underwent clinical examination, and blood samples were 
taken. Calcium intake, length and weight, use of disease modifying anti-rheumatic 
drugs (DMARDs), anti-osteoporotic drugs, and corticosteroids during the last 5 years 
were recorded.  
Bone mineral density measurement of hip and spine
The bone mineral density (BMD) was measured at baseline and after 5-year follow-
up. All measurements were performed on the same DXA machines as used in the 
baseline study.
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Statistical analysis
Statistical analyses were performed using the SPSS (Chicago, IL), version 15.0.
Independent group differences were tested by two-sided t-tests for continuous 
variables and chi-square tests for counts. Possible predictors of bone loss were explored 
in univariate regression analyses and associations with p<0.2 were subsequently 
entered into a multivariate linear regression analysis (backward procedure), applying 
BMD change during follow-up as the dependent variable. Standard diagnostic tests 
were performed, all tests were two-sided and p<0.05 was considered statistically 
significant.
RESULTS
Patient characteristics
Patient characteristics at baseline and 5-year follow-up are presented in Table 1.
Changes in BMD
There was a significant decrease of 5.9% (p<0.05) in total-hip BMD (g/cm2) from 
0.843 (0.156) to 0.793 (0.151). At the spine (L2–L4) there were a trend toward a loss 
(-2.4%, p=0.059) from mean BMD (g/cm2) 1.045 (0.190) at baseline to 1.020 (0.187) 
at 5 years. In Figure 1A and 1B probability plots display 5-year BMD for all patients 
and per center. Patients in Amsterdam tended to loose more bone at the spine than 
in Oslo and Truro (p<0.05). 
Determinants of bone loss
In the prediction model changes in BMD use of anti-resorptives was the only 
independent predictor for changes in BMD of the spine and hip (Table 2). Daily 
calcium intake, cumulative prednisone use, baseline BMD, baseline HAQ and disease 
duration were also entered into the model, but did not contribute significantly to the 
model when correcting for age and center.
DISCUSSION
In this observational study over 5 years we found a significant decrease in BMD at the 
total-hip of 5.9%, while at the lumbar spine there was a strong trend towards bone loss 
(-2.4%, p=0.06). This is a remarkably high rate of generalized bone loss, especially at 
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Table 1 Characteristics of the 102 patients
* Used for some time (> 1 month) during the studied period. 
§ All patients had discontinued HRT before the end of the study.
Baseline
Age [years] Mean (SD) 61 (6)
Disease duration [years] Median (range) 17 (6-25)
IgM-RF [positive] n (%) 67 (65)
DAS-28 Mean (SD) 5.4 (1.3)
HAQ Mean (SD) 1.48 (0.62)
Follow-up
DAS-28 Mean (SD) 3.6 (1.2)
HAQ Mean (SD) 1.59 (0.89)
Use of corticosteroids 
Used* n (%) 65 (64)
Mean cumulative dose [mg] Mean (SD) 2,900 (1,800)
Osteoporosis medication
Anti-resorptives* n (%) 57 (56)
Bisphosphonates* n (%) 31 (30)
HRT*§ n (%) 31 (30)
Calcium supplementation* n (%) 51 (50)
Vitamin-D supplementation* n (%) 43 (42)
Use of DMARDs
MTX* n (%) 66 (65)
SASP* n (%) 28 (27)
Anti-TNF* n (%) 20 (20)
Other* n (%) 44 (43)
Disease activity
Mean ESR [mm/hr during study] Median (range) 20.9 (11.8)
Mean CRP [mg/l during study] Median (range) 12.6 (10.9)
Table 2 Predictors of BMD change at hip and spine corrected for age and center
 B SE p
R2 = 0.09
Change in hip BMD
Anti-resorptive drugs 0.032 0.013 0.015
Constant -0.021 0.068
R2 = 0.11    
 Change in spinal BMD
Anti-resorptive drugs 0.086 0.027 0.035
Constant -0.303 0.142
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Figure 1A and 1B Probability plot of the change of BMD (g/cm2) at hip and spine during 
the 5-year follow-up for all patients and per center.
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the hip, during a time period in which treatment of RA is dramatically improved by 
the use of combination therapy with conventional drugs or biologicals, for instance 
TNF-blockers [13].
We compared our data to other studies investigating changes in BMD: in a study by 
Shibuya et al. a decrease in spinal BMD of 1% during 1 year follow-up in an unselected 
cohort of 146 RA patients was found [8]. Haugeberg et al. also investigated the change 
of BMD in a population based cohort of RA patients and found a decrease of -0.77% 
at the total hip to -0.29% at the spine during 2 years [6]. In this study patients using 
HRT or bisphosphonates had a lower rate of bone loss. Studies excluding patients with 
anti-osteoporotic treatment tend to find a higher rates of bone loss, for example Cortet 
et al. found a loss of 2.1% at the spine and 3.1 at the hip in a cohort of RA patients 
during 18 months follow-up [7]. As in our study the bone loss seems to be greater at 
the hip than that at the spine. 
When we compare our data to an osteoporotic female population without RA of 
comparable age, we found a higher rate of generalized bone loss in our study; for 
example the placebo arm of a randomized control trial investigating the effect of 
treatment with alendronate in postmenopausal women, these patients showed non-
significant decreases in BMD of the spine and hip of respectively 0.6% and 0.7% 
during 3 years [10]. 
Several studies have shown that active treatment of RA limits BMD loss. In a previous 
1 year study in RA patients treated with anti-TNF we showed that there was no loss 
of bone at hip and spine, this was especially true for the group of patients who had 
a good clinical response on anti-TNF. In this study we did not find an association 
between BMD loss and disease activity markers or treatment with anti-TNF drugs. 
Only use of anti-resoprtives (bisphosphonates and HRT) was an independent 
predictor of change in BMD at the hip or spine. It is difficult to investigate factors 
associated with BMD changes in RA patients because of the multifactorial nature 
of both diseases and the possible interactions between variables (i.e. corticosteroids 
suppress disease activity but also decrease BMD). This could be one of the reasons 
why we found so few predictors for change in BMD. Another reason of course could 
be due to the size of the cohort. 
In conclusion this is one of the first studies investigating BMD changes in RA patients 
over a long period (5 years). We found that even in a postmenopausal population 
with established RA of which one third was treated with bisphosphonates, there 
was still a substantial decrease in BMD of 5.9% at the hip and a 2.4% bone loss at 
the spine. 
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Chapter 3c
ABSTRACT
Objective: The objective of this study was to examine 5-year change in cortical hand 
bone mineral density (BMD) in female rheumatoid arthritis (RA) patients with 
established disease. Further, possibly baseline predictors of 5-year loss in DXR-BMD 
were studied.
Methods: This 5-year multicenter, longitudinal study included patients from Amster-
dam (the Netherlands), Truro (UK) and Oslo (Norway). At baseline 50 patients were 
consecutively included per centre. Inclusion criteria were: Female sex, age 50–70 years 
and disease duration ≥ 5 years. This study presents 5-year follow-up data for 85 of 
these 150 patients (29 from Amsterdam; 26 from Truro; and 30 from Oslo). Clinical 
examination, blood test and radiographs were taken at baseline and 5-year follow-up. 
Cortical hand BMD was measured by Digital X-ray radiogrammetry (DXR) from 
hand radiographs.
Results: The mean (95% CI) baseline DXR-BMD for all patients was 0.46 g/cm2 (0.44 
to 0.48) and the median 5-year DXR-BMD change was -6.7% (-11.2 to -2.82). 5-year 
DXR-BMD loss was associated with baseline measurements of age, RF, CRP, HAQ and 
DAS-28 in univariate linear regression analyses. DAS-28 at baseline was an independent 
predictor of 5-year DXR-BMD loss in multivariate linear regression analyses corrected 
for centre, age and use of bone protective agents.
Conclusion: High disease activity measured by DAS-28 was an independent predictor 
of cortical hand bone loss over 5 years in established, destructive RA. This finding 
supports that increased disease activity leads to localised bone loss in longstanding 
RA and underlines the importance of tight control and aggressive anti-inflammatory 
treatment in this patients.
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INTRODUCTION 
Periarticular bone loss is an early characteristic feature of rheumatoid arthritis (RA) 
visible on radiographs and together with erosions considered a hallmark of the disease 
[1]. Inflammatory activation of the osteoclast is involved in both features. Studies support 
that cytokines such as TNFα, interleukin-1 (IL-1), IL-6, macrophage colony-stimulating 
factor and receptor activator of nuclear factor-κ ligand (RANKL), activate the osteoclast 
which causes osteoporosis (localised and generalised) and erosions [2-4]. 
Quantitative hand bone loss can be measured by dual energy X-ray absorptiometry 
(DXA) bone mineral density (BMD) which measure the total amount of local bone 
[5] and digital X-ray radiogrammetry (DXR) which measures cortical bone [6]. The 
advantage of DXR is that BMD can be analysed from hand radiographs, often taken 
routinely of RA patients in daily clinical practice. Previous studies suggest that DXA 
measured bone loss only takes place the first 2-3 years after disease start [7-9], while 
one study suggest that DXR measured loss occur through the whole disease course [9]. 
However, there is limited information concerning hand bone loss in established RA. 
Inflammation of the joints is not restricted to the early phase of the RA disease, but 
may be present during the entire disease course [10]. Hence, theoretically one could 
consider applying hand bone as an outcome measure also in established RA.
The main objective of this multi-centre observational study was to examine 5-year 
change in hand DXR-BMD in RA patients with established disease and to possibly 
identify baseline predictors of 5-year change in DXR-BMD. 
METHODS 
Patients
The original cohort consisted of 150 women with established RA who were recruited 
from rheumatology clinics in Amsterdam, the Netherlands; Truro, UK; and Oslo, 
Norway. At baseline 50 patients were consecutively included per centre and inclusion 
criteria were: female sex, age 50–70 years and RA disease duration ≥ 5 years [11]. Hand 
BMD measured with DXR was performed in 135 of the original cohort at baseline [12]. 
We now present 5 year follow-up data for DXR-BMD for 85 of these patients (29 from 
Amsterdam; 26 from Truro; and 30 from Oslo). A flow-chart of the patients is depicted 
in Figure 1. Disease activity at baseline was assessed by joint counts (28-tender and 
28-swollen joint counts), patient and physician’s global assessment of disease activity 
and by acute phase reactants. The disease activity score DAS-28 was computed based 
on erythrocyte sedimentation rate (ESR) [13].
61
Radiographs and DXR-BMD analyses 
DXR (Sectra, Linköping, Sweden) was used to measure hand BMD on bilateral hand 
radiographs taken in postero-anterior view. DXR is a computer version of the traditional 
radiogrammetry technique [14] and the method has previously been described in detail 
[6]. On hand radiographs, the computer automatically recognizes regions of interest 
around the narrowest part of the second, third, and fourth metacarpal bone and measure 
cortical thickness, bone width and porosity 118 times per cm. DXR-BMD is defined 
as c X VPAcomb X (1-p), where c is a density constant, VPA is cortical volume per area, 
and p is porosity. To avoid bias regarding dominant and non-dominant hands and to 
achieve better precision, we used the mean of both hands [15]. If the radiograph from 
one hand could not be analysed, we used the radiograph from the available hand for 
analyses at both time points. At baseline all radiographs were conventional films and 
DXR-BMD were analysed with Pronosco X-posure 2.0. Short-time precision (coefficient 
of variation, CV%) for Pronosco X-posure based on duplicate hand radiographs with 
reposition between each measurement in healthy individuals has been found to be 
0.28% for mean of both hands [9]. At 5-years follow-up DXR-BMD for the radiographs 
from Amsterdam (conventional) and Truro (digitised and printed out) were analysed 
with the same Pronosco X-posure 2.0 equipment, while the radiographs from Oslo 
were digitised and analysed with dxr-online (Sectra, Sweden). The same algorithm 
was used for calculating DXR-BMD both in Pronosco X-posure and dxr-online. 
However, analysing digitised radiographs has been shown to be more influenced by 
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Figure 1 Flow-chart of the included patients in the present study. A, Amsterdam; T, Truro; 
O, Oslo.
Baseline 150 patients included
48 patients lost 
for follow-up (13 
died, 5 severe 
co-morbidity, 30 
refused to follow 
up or moved from 
the area)
102 patients 
follow-up
150 hand X-rays 
available
15 DXR-BMD could 
not be analysed 
(severely damaged 
joints, metals in 
the metacarpals)
94 hand X-rays 
available
7 excluded 
(severely damaged 
joints, metals in 
the metacarpals)
85 patients with 
DXR analysed at 
both baseline and 
5-year follow-up 
(A: 29; T: 26; O: 30)
5-year follow-up
the radiographic equipment than conventional radiographs [16-18]. Seven patients’ 
radiographs failed DXR-BMD analyses due to severely damaged joints or metal implants 
at 5-year follow-up. These patients showed a trend toward a longer disease duration 
(20 vs. 13.5 years, p=0.12) and older age (59.6 vs. 62.4 years, p=0.27). 
The baseline radiographs of the hands and wrists were scored according to the van 
der Heijde modified Sharp score (vdHSS) by a trained observer (PB) [19]. 
Statistical methods
The analyses were performed using SPSS 14 statistics package (SPSS Inc, USA). 
Baseline characteristics were described using median and inter quartile range (IQR) for 
continuous variables and percentage for counts. Independent groups were compared 
using Mann-Whitney U test for continuous variables, χ2-tests for dichotomous variables 
and Kruskall Wallis for differences between centres. DXR-BMD change was calculated 
as the percentage difference between the follow-up value and the baseline value and 
bone loss over time was expressed as a negative value. The individual 5-year DXR-
BMD changes were depicted in cumulative probability plots [20]. 
Possible predictors for 5-year DXR-BMD loss were examined by univariate linear 
regression analyses. The independent variables with a p-value ≤ 0.20 were included 
in multivariate linear analyses with 5-year changes in DXR-BMD as the dependent 
variable. The final multivariate model was obtained by enter procedure and standard 
diagnostic tests of model assumptions and residuals were routinely performed. 
All tests were two-sided and p-values ≤ 0.05 were considered to be statistically 
significant.
RESULTS
Baseline characteristics
Baseline characteristics comparing patients with and without 5-year DXR-BMD 
measurements are presented in Table 1, and the patient flow is presented in Figure 1. 
The 85 included patients were younger, had a significantly lower ESR, HAQ and they 
also had significantly higher DXA of the total hip compared with those who were not 
included (n=65) from the original study (Table 1). The two groups were comparable 
regarding disease duration, positive rheumatoid factor, DAS-28 and use of DMARDs, 
prednisolone and bone protective treatment. There were no significant differences in 
the number of patients from the different centres available for follow-up at 5 years (29 
from Amsterdam; 26 from Truro; and 30 from Oslo, p=0.88, χ2-tests). 
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Baseline and follow-up treatment are summarised in Table 1. Overall, 52% of the patients 
used bone protective treatment (defined as bisphosphonates, estrogens or raloxifen) 
during follow-up. The patients receiving bone protective treatment at baseline had 
similar DAS-28 as those who did not (4.8 vs. 4.5, p=1.0). None of the patients were treated 
with teriparatide or calcitonin. Anti-TNFα therapy was used by 19% of the patients.
DXR-BMD change during the follow-up period
The mean (95% CI) baseline DXR-BMD for all patients was 0.46 g/cm2 (0.44 to 0.48) 
and the median (IQR) 5-year DXR-BMD change was -6.7% (-11.2 to -2.82). The 
individual 5-year DXR-BMD losses stratified for centre are depicted in a cumulative 
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† Mann-Whitney U for continuous variables, χ2-tests for categorical variables; * p≤0.05. IQR, inter quartile range; 
BMI, body mass index; HAQ, health assessment questionnaire; ESR, erythrocyte sedimentation rate; DAS-28, 
disease activity score; vdHSS, van der Heijde Sharp score; DMARDs, disease modifying anti-rheumatic drugs; Bone 
protective agents, use of estrogens or bisphosphonates during follow-up.
Table 1 Baseline characteristics of female patients with rheumatoid arthritis with and 
without hand bone density measurements (Median (IQR) or absolute value (percent))
Patients with 
DXR-BMD measurements
n=85
Patients without 
DXR-BMD measurements
n=65 p-value†
Demographic variables
Age (years) 59.7 (54.8–64.3) 64.0 (58.8–67.9) <0.01*
Menopause 74 (87%) 64 (99%) 0.01*
BMI (kg/m2) 25.5 (22.8–27.4) 24.3 (22.6–27.8) 0.78
Smoker (current) 24 (28%) 24 (37%) 0.40
Disease duration (years) 13.5 (9.5–21.6) 16.5 (10.0–23.0) 0.46
HAQ (range 1–4) 1.50 (0.88–1.88) 1.87 (1.14–2.25) 0.01*
Disease variables
Rheumatoid factor positive 51 (60%) 43 (66%) 0.44
ESR (mm/hour) 18.0 (10.0–29.0) 23.5 (13.0–40.8) 0.03*
DAS-28 4.8 (4.1–5.6) 5.0 (4.1–5.8) 0.43
Radiographic damage (vdHSS) 16 (5–42) NA
Medication at baseline
DMARDs 62 (73%) 46 (71%) 0.46
Corticosteroid                          28 (33%) 29 (45%) 0.19
Bone protective agents 51 (60%) 39 (60%) 1.00
Medication during follow-up
Anti-TNFα therapy 16 (19%) NA
Corticosteroid 40 (47%) NA
Bone protective agents 44 (52%) NA
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probability plot (Figure 2). The median (IQR) 5-year DXR-BMD change in Amsterdam, 
Truro and Oslo were -5.1% (-10.7 to -2.4), -8.1% (-12.4 to -5.2) and -6.9% (-10.7 to 
-2.8), respectively. There were no statistically significant differences between the centres 
(p=0.19, Kruskall Wallis test). The vdHSS change during the 5-year follow-up period 
was median 8 units (interquartile range 0–16.5). The correlation between 5-year change 
in hand DXR-BMD and vdHSS was -0.24 (p=0.04).
Associations between 5-year DXR-BMD change and baseline character-
istics and prediction of hand bone loss
The associations between 5-year change in DXR-BMD and baseline variables and 
treatment during follow-up are presented in Table 2. Five-year DXR-BMD loss was 
significantly associated with lower age, positive RF, elevated CRP, HAQ and DAS-28 
in univariate linear regression analyses. 
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† Amsterdam used as reference. * p-value ≤ 0.05. Covariates eligible for multivariate analyses are marked in bold. 
BMI, body mass index; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; HAQ, health assessment 
questionnaire; DAS-28, disease activity score based on 28 joint count; DXR-BMD, digital X-ray radiogrammetry; 
TNFα, tumour necrosis factor α.
Table 2 Associations between 5-year DXR-BMD change (follow-up minus baseline) and 
baseline characteristics as well as treatment during follow-up (univariate linear regression 
analyses)
B 95% CI p-value
Center† Oslo -1.2 -4.7 – 2.3 0.50
                       Truro -3.2 -6.8 – 0.4 0.08
Age 0.2 -0.01 – 0.5 0.06
Age (grouped into 50–59 vs. 60–70) 3.8 1.0 – 6.6 0.009*
Disease duration (years) -0.04 -0.2 – 0.1 0.60
BMI (kg/m2) 0.1 -0.3 – 0.5 0.60
Swollen joints -0.3 -0.6 – 0.02 0.06
Tender joints -0.2 -0.4 – 0.05 0.12
ESR (mm/hr) -0.1 -0.1 – 0.04 0.30
CRP (mg/L) -0.1 -0.2 – -0.02 0.02*
RF (negative vs. positive) -3.5 -6.5 – 0.4 0.02*
HAQ -2.1 -4.3 – -0.02 0.05
DAS-28 -2.0 -3.2 – -0.7 0.002*
Baseline DXR-BMD -8.2 -26.3 – 9.8 0.37
Prednisolone during follow-up (yes/no)
Total dose of Prednisolone (g)
-0.4
4x10-5
-11.3 – 10.6
0.0 – 0.0
0.95
0.42
Anti-TNFα therapy during follow-up (yes/no)
Duration of anti-TNF-α therapy (months)
0.7
0.01
-3.2 – 4.5
-0.1 – 0.1
0.73
0.85
Bone protective agent during follow-up 2.3 -0.7 – 5.4 0.13
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Figure 3 Cumulative probability plots of 5-year DXR-BMD change (%), stratified for high 
disease activity (DAS-28 > 5.1) versus moderate/low disease activity (DAS-28 ≤ 5.1).
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Figure 2 Cumulative probability plot of 5-year DXR-BMD change (%) stratified by centre.
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Baseline DAS-28 was maintained as an independent predictor of 5-year change in DXR-
BMD in the final multivariate linear regression model. The final model explained 31% 
of the variation (R2) in DXR-BMD change and was corrected for age, centre and use 
of bone protective agents. The effect of disease activity on hand bone loss is illustrated 
by a cumulative probability plot depicting the 5-year DXR-BMD change stratified 
for high (DAS-28 > 5.1) versus low and moderate disease activity (Figure 3). DAS-28 
of 5.1 is the cut point between moderate and high disease activity and was therefore 
selected as a cut-off for high disease activity [21].
DISCUSSION
The main finding in this study was that baseline disease activity independently 
predicted hand BMD loss in postmenopausal patients with established, severe RA. 
Only few studies have examined associations between disease factors and hand bone 
loss in RA, but most of these studies have focused on early disease [7, 8, 9, 15, 22, 
23]. The change in DXA-BMD hand and DXA bone mass content (BMC) has been 
found to be inversely correlated to elevated baseline CRP levels and the presence of 
RF [7, 8, 15]. However, loss of DXA-BMD and DXA-BMC has been suggested to 
occur only in patients with disease duration less than 2–3 years may limit the use 
of hand DXA-BMD in established disease [7-9]. Degenerative bone changes and 
increased inflammation in the small joints of the hand in the first years of the disease 
has been suggested partly to explain this finding [5, 7, 9]. The fact that DXR-BMD 
and DXA-BMD are based on different techniques and the precision for the DXR-
method [18, 24, 25] is superior to the DXA method [26-28] may also contribute to 
this difference.
There are a few studies concerning disease activity as a predictor for DXR-BMD. In 
early RA both loss of DXR-BMD and DXR metacarpal cortical index (MCI) has been 
predicted by high CRP [22, 29], high ESR and anti-CCP [23, 30]. Only one previous 
study has shown that high DAS-28 predicted DXR-BMD loss in established RA [9]. 
However, this previous study only had follow-up of 2 years, but included a larger 
number of patients than the current study. 
The DAS-28 levels were improved during the 5-year follow-up from 4.8 to 3.8 
(p<0.001). The main reason for this is probably the introduction of anti-TNF therapy 
and a more aggressive treatment with combination of DMARDs. 
Despite improvement of DAS-28 during the follow-up period, the patients experienced 
a significant decline in cortical hand BMD, suggesting that this bone loss is chronic 
and progressive.
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Another observation in the present study was that the youngest age group lost more 
hand BMD than the oldest age group. In order to look at the possible impact of 
menopause on hand bone loss, we dichotomised the age into under and above 60 
years, this also coincided with the median age. An earlier 10-year longitudinal study 
have suggested that the menopause, and not age per se was determining the start of a 
period with increased rate of bone loss [31]. However, some studies suggest that bone 
loss is increasing after menopause and then decline with age [32], while others suggest 
an increased constant bone loss [31]. This study might support that bone loss is larger 
in the first years after menopause [32], and suggest that not only increased generalised 
bone is observed in early postmenopausal women, but also that local hand bone loss is 
elevated. However, this result may be biased by the fact that the drop-outs were older 
than the participants (64 vs. 60 years, p<0.001). 
The effect of medical treatment on bone was difficult to evaluate in this study due 
to the observational study design and the unstandardised patient treatment. In RA 
patients, adverse effects on bone by corticosteroids are of clinical importance [33, 34]. 
However, suppressing inflammation by corticosteroids has been found to increase hand 
DXR-BMD in two studies [22, 35], which may suggest that the anti-inflammatory effect 
overweighs the negative corticosteroid effect on bone. In the present study the use of 
corticosteroids was not associated with cortical bone loss, which might be due to the 
treatment with bone protecting agents. Use of bone protecting agents during follow-up 
was non-significantly associated with a decreased loss in DXR-BMD (Table 2) which 
may suggest that this treatment might not only have a beneficial effect on generalised 
bone loss and fractures but also on cortical hand bone loss in RA. Previous studies are 
conflicting in their results as to the effect of anti-resorptive treatment on hand BMD 
[22, 36, 37]. Anti-TNFα therapy has also been found to decrease bone loss in early RA 
patients [22, 38]. In this study treatment with anti-TNFα therapy was not associated 
with DXR-BMD change, which might be explained by the long disease duration, high 
disease activity and the low proportion (19%) of users of anti-TNFα therapy as well 
as confounding by indication.
The main limitation of this study was that the 5-year follow-up radiographs were 
analysed in three different ways. This was due to difficulties of analysing DXR-BMD 
in the three different centres as mentioned under the method section. However, DXR-
BMD change did not differ between the three centres and the 5-year DXR-BMD median 
percentage changes for all centres were -6.7% which exceeds the possible source of 
error for the analysing methods. Based on these observations, we do not think the bias 
of this different analyses affect the main conclusion. Another limitation to the DXR 
method is that it can not be applied on radiographs of RA patients with severe joint 
damage. In the present study 10 and 7% of the baseline and follow-up radiographs 
could not be analysed for this reason.
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Conclusion
In this study we found that RA patients with established disease experienced substantial 
cortical hand bone loss. This bone loss was independently predicted by high disease 
activity. 
This finding indicates that increased disease activity leads to localised bone loss in 
longstanding RA which supports the importance of tight control and aggressive 
antiinflammatory treatment also in patients with established disease.
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Chapter 4a
ABSTRACT
Background: Cardiovascular morbidity and mortality appear to be enhanced 
in rheumatoid arthritis (RA) which might be due to an increased prevalence of 
cardiovascular risk factors such as dyslipidemia. It was recently shown that effective 
DMARD treatment had a favourable influence on the lipid profile in active RA. As 
infliximab markedly reduces disease activity in RA, the effects of infliximab on the 
lipid profile were examined.
Objective: To investigate the effect of infliximab on the lipid profile in patients with 
active RA.
Methods: Patients with active RA (defined as a Disease Activity Index 28 score ((DAS-
28) of at least 3.2) were included. Infliximab (3mg/kg) was administered at baseline, 
2 and 6 weeks. Total cholesterol and HDL-cholesterol levels were measured and their 
ratio, the atherogenic index, which is an important cardiovascular risk factor, calculated 
to assess changes in lipid profiles.
Results: Sixty-nine patients were enrolled and DAS-28 (SD) was 5.9 (± 1.4) at baseline 
and decreased to 4.6 (± 1.4) after 2 weeks and further to 4.1 (± 1.5) after 6 weeks. Total 
cholesterol level was 5.2 mmol/l at baseline and increased to 5.7 mmol/l (p<0.001) 
at 2 weeks and was 5.6 mmol/l (p<0.001 vs baseline) at week 6. For HDL-cholesterol 
these values were 1.5, 1.6 (p<0.001) and 1.6 mmol/l (p<0.001 vs baseline), respectively. 
Linear regression showed that changes in disease activity (DAS-28) were significantly 
inversely associated with changes in total cholesterol and HDL-cholesterol levels. The 
atherogenic index however remained constant during these six weeks of infliximab 
treatment. Corticosteroid use at baseline was associated with a significantly higher 
total cholesterol and HDL-cholesterol levels and a lower more favourable atherogenic 
index at baseline.
Conclusions: Treatment with infliximab induced a significant increase in levels of 
both total cholesterol and HDL-cholesterol, which was correlated with a decrease 
in disease activity. However this was not accompanied by a favourable effect on the 
atherogenic index. 
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INTRODUCTION 
Mortality appears to be increased in patients with rheumatoid arthritis (RA) compared 
to the general population, and cardiovascular disease is the most important cause of 
death [1]. Theoretically, this increased cardiovascular risk in RA patients could be 
caused by (1) an increased prevalence of classical risk factors for cardiovascular disease 
such as dyslipidemia, diabetes mellitus, hypertension, body mass index, physical fitness 
and smoking habits (2) RA itself by either a) the underlying inflammatory process, 
or b) decreased functional capacity c) DMARD therapy, and (3) under-treatment of 
cardiovascular co-morbidity. This increased cardiovascular risk is also evidenced by 
an increased prevalence of sub-clinical atherosclerosis as assessed by increased carotid 
intima-media thickness in patients with RA in comparison with healthy controls [2, 
3].
We previously demonstrated that active RA is associated with an unfavourable lipid 
profile, i.e. decreased total cholesterol and relatively more depressed HDL-cholesterol 
levels in comparison with age and sex-matched RA patients in remission [4]. This so-
called atherogenic index i.e. the ratio between total cholesterol and HDL-cholesterol, 
which is an important cardiovascular risk factor, tended to normalise upon anti-
rheumatic treatment. This normalisation occurred more rapidly in combination 
treatment with methotrexate, sulphasalazine and corticosteroids as compared with 
treatment with sulphasalazine alone [4]. Ultimately, these favourable alterations of 
the lipid profile could result in a lower cardiovascular risk. The beneficial effects of 
antirheumatic treatment in the above mentioned investigation could be mediated 
either through a direct effect of corticosteroids or indirect by influencing the disease 
activity.
Literature regarding the effect of treatment with anti-TNF blocking agents on the lipid 
profile in RA patients with active disease is scarce. Only one group investigated the 
effect of anti-TNF in a very limited number RA and psoriatic arthritis patients. They 
found that the lipid profile changed into a more atherogenic profile during treatment 
with infliximab [5]. 
Therefore, we prospectively investigated the effects of the anti-tumor-necrosis-factor 
(TNF) infliximab, a drug which has no known direct effects on the lipid profile, in 
large cohort of patients with active RA. 
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PATIENTS AND METHODS 
Consecutive patients with active RA (defined as a Disease Activity Index 28 Joint 
Score (DAS-28, [6]) of at least 3.2) who were referred to the Slotervaart hospital for 
treatment with infliximab, were included. All patients fulfilled the ACR 1987 criteria of 
RA [7]. Infliximab (3mg/kg) was administered at 0, 2 and 6 weeks. All blood samples 
(non-fasting) were collected, in the morning, prior to each infusion and stored at 
-70 °C for a maximum of 6 months until lipid determinations. Total cholesterol, and 
HDL-cholesterol levels were measured and their ratio calculated to assess changes in 
lipid profiles.
At each visit erythrocyte sedimentation rate, C-reactive protein, Visual Analogue 
Scale of general health, number of swollen and tender joints were assessed in order 
to determine disease activity (DAS-28 score). Changes in medication were recorded 
at each visit.
Total cholesterol and HDL-cholesterol determinations 
Total serum cholesterol (N: 5.0–6.4 mmol/l) was measured by an enzymatic method 
in an autoanalyser; HDL-cholesterol (N > 0.9 mmol/l) was determined enzymatically 
with PEG-modified enzymes.
Although, the classical (chemical) reference value considers a total cholesterol value of 
6.4 mmol/l as the upper limit of normal we have, for the interpretation of our results, 
chosen 5.0 mmol/l as the upper limit in view of the recommendations made by several 
national and international consensus committees [8, 9]. These guidelines were made 
in view of the increasing evidence that “high-normal” total cholesterol serum levels 
already imply an increased cardiovascular risk.  
Statistical analysis
Total cholesterol, HDL- and the total cholesterol / HDL-ratio (atherogenic index) at 
2 and 6 weeks were normally distributed and therefore compared to baseline with 
paired t-tests.
To investigate the association between the changes in lipid profiles (outcome variables) 
and changes in disease activity, linear regression analyses were performed for the period 
from 0 to 2 weeks and the period from 0 to 6 weeks. Two analyses were done: one 
crude without adjustments and one adjusted for age, disease duration, sex and change 
in prednison dose. All analyses were carried out with SPSS (version 11.0).
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RESULTS
Patients
A total of 69 consecutive patients were enrolled, with the following baseline characteristics 
(Table 1): 55 (80%) female, mean age 55 (13) years, mean disease duration 12 years 
(range 0–59 years) and 48 (70%) rheumatoid factor positive. At entry, 90% of patients 
used methotrexate (MTX) (mean dose 15.8 mg/week) and five patients used other 
DMARDs (Table1).
Thirty-two patients used corticosteroids at the start of the study (mean prednisone dose 
10.6 mg/day). In the patients using prednisone; 19 patients kept a stable dose whereas 
in 13 patients the dose was decreased because of a good response to infliximab. DAS-28 
score was 5.9 (1.4) at baseline and decreased to 4.6 (1.4) after 2 weeks (p<0.001) and 
further to 4.1 (1.5) after 6 weeks (p<0.001) (Table 2).
Total cholesterol and HDL-cholesterol
Total cholesterol level and HDL-cholesterol were was 5.17 mmol/l and 1.47 mmol/l at 
baseline respectively. Total cholesterol and HDL-cholesterol levels were significantly 
higher at baseline in the steroid user group than in the patients without steroid 
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Table 1 Baseline characteristics of 69 RA patients
Baseline characteristics 
Age (years)
Mean (SD) 55 (13)
Range 24–80
Female, n (%) 55 (80)
Rheumatoid factor postive, n (%) 48 (70)
Mean duration of disease, years (range) 12 (0–59)
DAS-28 at baseline, mean (SD) 5.9 (1.4)
Treatments 
Steroids, n (%) 32 (46)
Mean dose, mg (range) 10.6 (2.5–30)
Methotrexate, n   62 (90)
Mean dose, mg (range) 10.8 (2.5–30)
Other DMARDs, n
D-penicillamine 1
Azathioprine 3
Cyclosporine 1
Hydroxychloroquine 5
treatment (respectively 5.52 vs. 4.86 p<0.001 and 1.72 vs 1.25 p<0.001). This resulted in 
a more favourable atherogenic index in the steroid user group, at baseline (respectively 
3.41 vs. 4.10, p<0.05). Age, gender, and disease activity were not significantly different 
between these groups.
Total cholesterol increased from 5.17 mmol/l to 5.70 mmol/l (p<0.001 vs. baseline) at 
2 weeks and was 5.52 mmol/l (p<0.001 vs. baseline) at week 6. The values for HDL-
cholesterol were 1.47, 1.60 (p<0.001 vs. baseline) and 1.59 mmol/l (p<0.001 vs. baseline) 
respectively. The atherogenic index however remained constant during the six weeks 
of infliximab treatment (Table 2).
To assess whether changes in the lipid profile were associated with a change in 
disease activity we performed linear regression analyses. The changes in HDL- and 
total cholesterol from 0 to 2 weeks showed no significant association with changes in 
DAS-28. However, changes in DAS-28 from 0 to 6 weeks were significantly inversely 
associated with changes in both total- and HDL-cholesterol levels (Table 3). This 
association remained after adjusting for changes in prednisone dose, age, sex and 
disease duration. Although the mean atherogenic index did not change, changes in 
DAS-28 were significantly associated with changes in the atherogenic index in the 
period from 0 to 2 weeks. 
However, this association disappeared when considering the whole study period (from 
0 to 6 weeks) (Table 3).
Because prednisone had a significant confounding effect in our model, we performed 
the same regression analyses for the change in prednisone. Changes in prednisone dose 
were significantly associated with the changes in HDL and inversely associated with 
the atherogenic index from 0 to 6 weeks (respectively B= 0.031, p=0.005 and B=0.0453, 
p=0.047). This association remained after adjusting for the change in disease activity. 
No other relations between changes in prednisone and lipid profile were found at 
either of the intervals. 
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Table 2 DAS-28, ESR, total cholesterol, HDL-cholesterol and atherogenic index (cholesterol/
HDL-cholesterol) levels during the 6-week treatment
* p<0.001 compared to baseline.
Baseline 2 weeks 6 weeks
DAS-28 5.9 (1.4) 4.9* (1.4) 4.1* (1.5)
Total cholesterol mmol/l (SD) 5.17 (1.06) 5.7* (1.17) 5.52* (1.24)
HDL-cholesterol mmol/l (SD) 1.47 (0.43) 1.60* (0.47) 1.59* (0.50)
Atherogenic index  3.8 (1.2)    3.7 (1.1) 3.7 (1.2)
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DISCUSSION
We found slightly elevated total cholesterol levels and normal HDL-cholesterol levels 
in RA patients with active disease at baseline. Treatment with infliximab induced a 
significant increase in levels of both total cholesterol and HDL-cholesterol. However, 
these changes did not alter the atherogenic index which is an important prognostic 
marker for future cardiovascular disease. The increases in cholesterol levels were 
significantly associated with a decrease in disease activity. 
The stable atherogenic index over the studied period contrasts with findings in early 
RA-cohorts [4, 10]. One trial, investigating combination DMARD therapy (including 
corticoids), indicated a favourable effect on the atherogenic index. However, this 
study was performed in early RA patients. The explanation could be that rheumatoid 
cachexia [11], with accompanying low cholesterol levels and relatively lower HDL-
cholesterol levels, is more prominent in early RA than in established RA. The other 
study demonstrated decreasing HDL-cholesterol levels during treatment with 
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Table 3 Results of the linear regression models to evaluate the association between 
changes in lipid profile and changes in DAS-28 from 0 to 2 weeks and 0 to 6 weeks
 Coefficient Significance 95% CI
B p Lower Upper
Changes HDL from 0 to 2 weeks
Changes in DAS-28 -0.04 0.13 -0.083 0.011
Corrected -0.04 0.14 -0.084 0.012
Changes HDL from 0 to 6 weeks
Changes in DAS-28 -0.06 0.01 -0.099 -0.014
Corrected -0.05 0.01 -0.093 -0.012
Changes total cholesterol from 0 to 2 weeks
Changes in DAS-28 0.02 0.77 -0.125 0.168
Corrected 0.01 0.88 -0.1 0.157
Changes total cholesterol from 0 to 6 weeks
Changes in DAS-28 -0.15 0.02 -0.27 -0.025
Corrected -0.16 0.01 -0.28 -0.042
Changes atherogenic index from 0 to 2 weeks
Changes in DAS-28 0.14 0.01 0.04 0.245
Corrected 0.13 0.02 0.03 0.238
Changes atherogenic index from 0 to 6 weeks
Changes in DAS-28 0.05 0.23 -0.03 0.140
Corrected 0.04 0.41 -0.05 0.121
The corrected model gives the results of the studied relation after correction for age, sex, disease duration and 
changes in prednisone dosage.
infliximab leading to a less favourable atherogenic index [4]. However, in this latter 
study only seven RA and eight psoriatic arthritis patients were studied, hence a 
chance finding cannot be excluded.
Thus far the literature is contradictory regarding the effect of corticosteroids on lipid 
profile in RA and data of properly designed studies are lacking. The results of this 
study indicate that use of corticosteroids was, at baseline, associated with increased 
total cholesterol levels and, to a relatively greater extent, increased HDL-cholesterol 
levels. Consequently, a lower atherogenic index, in prednisone users in comparison 
to non-prednisone users, was observed at baseline. Lowering the prednisone dose 
was associated with a decreasing HDL-cholesterol level, and an increase of the 
atherogenic index. Whether or not this favourable effect of corticosteroids on the 
lipid profile, at baseline, is ultimately offset by other cardiovascular side effects of 
corticosteroid use, e.g. hypertension or hyperglycemia, remains to be determined. 
The effect of lowering prednisone attenuates the effect of a decreasing disease activity 
(by infliximab) on the atherogenic index and could explain the observation that the 
atherogenic index did not change during the studied period.
Altogether, this study shows that short-term treatment with infliximab increases both 
total cholesterol and HDL-cholesterol and that this was associated with a decrease of 
disease activity. However, the atherogenic index remained constant due to lowering 
the prednisone doses. 
Hence, the favourable effect of infliximab on cardiovascular comorbidity observed in 
the literature appears not to be mediated by effects on the lipid metabolism [12]. 
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Chapter 4b
ABSTRACT
Objectives: To evaluate the effects of infliximab and corticosteroid therapy on the 
lipid profile in patients with active rheumatoid arthritis (RA).
Methods: Infliximab infusions were given at week 0, 2, 6 and then every 8 weeks. 
Prior to each infusion, disease activity parameters (DAS-28, CRP) and lipid levels 
(total-, high-density lipoprotein (HDL) cholesterol, triglycerides, apolipoprotein A-1 
(Apo A-1) and apolipoprotein B) were measured in 80 consecutive RA patients, who 
completed the study period of 48 weeks. Longitudinal analyses were used to investigate 
(1) the course of lipid levels over a period of time and (2) the relationship between 
lipids, prednisone dose and disease activity.
Results: Infliximab treatment causes a significant reduction in disease activity 
and a concomitant decrease of prednisone dose. Although they initially improved 
significantly, all lipid levels had returned to baseline levels after 48 weeks, except for 
Apo A-1. Longitudinal analyses reveal significant yet opposite associations between 
lipid levels and disease activity and between lipid levels and prednisone dose. DAS-
28 improvement by 1 point is associated with an increase of 0.016 mmol/l (0.618 
mg/dl) total- and 0.045 mmol/l (1.737 mg/dl) HDL-cholesterol. Reduction of 10 mg 
prednisone is associated with a decrease of 0.04 mmol/l (1.544 mg/dl) total- and 0.16 
mmol/l (6.177 mg/dl) HDL-cholesterol.
Conclusion: Overall, no changes in serum lipid levels were observed after 48 weeks 
of infliximab treatment. The initial beneficial effects of infliximab on the lipid profile, 
by means of a reduction of disease activity, are attenuated by a concomitant decrease 
in prednisone dose. 
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INTRODUCTION 
Rheumatoid arthritis (RA) is a chronic, inflammatory disorder of the joints. Patients 
with RA have an increased morbidity and mortality compared to the general population. 
Mortality due to cardiovascular disease (CVD) is the leading cause of death observed 
in patients with RA [1]. This excess cardiovascular mortality in patients with RA is 
predominantly due to accelerated atherosclerosis [2]. 
A well-known cause of atherosclerosis is an atherogenic lipid profile. In particular, 
low levels of high-density lipoprotein (HDL) cholesterol, and high levels of total 
cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides are associated 
with an increased prevalence of CVD in the general population [3]. An important 
prognostic indicator for future CVD is the atherogenic index, i.e. the ratio between 
total- and HDL-cholesterol [4]. New data indicate that apolipoproteins, which are 
protein parts of the lipoprotein complex, are possibly better predictors for CVD. High 
levels of apolipoprotein B (apo B) and an increased apolipoprotein B / apolipoprotein 
A-1 ratio (apo B / apo A-1) are associated with an increased cardiovascular risk, 
whereas higher levels of apolipoprotein A-1 (apo A-1) are protective for developing 
CVD [5, 6].  
Several studies reported that RA is associated with an unfavorable lipid profile, 
particularly, in patients with active disease [7-9]. These studies show that active RA is 
associated with lower levels of HDL-cholesterol compared to healthy controls leading 
to a higher, i.e. unfavorable, atherogenic index. Hence, an atherogenic lipid profile may 
be part of the cause of the increased cardiovascular risk in patients with RA.
There is growing evidence that inflammation in RA is associated with a worsening 
of the lipid profile [10, 11], which improves upon effective anti-rheumatic treatment 
[12, 13]. We previously reported that normalization of the lipid profile in patients 
with RA occurred more rapidly in combination treatment with methotrexate (MTX), 
sulfasalazine, and prednisone than in treatment with sulfasalazine alone, thereby 
demonstrating the temporal relationship between decreasing disease activity and 
improvement of the atherogenic index [14]. However, due to the limited duration of 
the study we were unable to answer the question whether this difference was due to 
improved disease suppression or changes in prednisone dose. 
In another study, we found that treatment with anti-tumour necrosis factor (aTNF) 
therapy leads to a significant increase of both total- and HDL-cholesterol levels, which 
was inversely related with disease activity. The atherogenic index, however, remained 
constant during the six weeks study period [15]. 
Thus far, data regarding lipid changes during immunosuppressive treatment are 
contradictory [16, 17] and studies observing lipid changes during long-term 
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immunosuppressive treatment are lacking. In the present study longitudinal analyses 
are performed to investigate (1) the longitudinal course of lipid levels, including 
apolipoproteins, over time during immunosuppressive treatment, i.e. infliximab, and 
(2) the longitudinal relationship between lipids and indicators of disease activity and 
between lipids and prednisone doses. 
PATIENTS AND METHODS 
Patients
Consecutive patients with active RA (defined as a Disease Activity Index 28 Joint 
Score (DAS-28) of at least 3.2) who were referred to the Slotervaart Hospital for 
treatment with infliximab were included. All RA patients fulfilled the American 
College of Rheumatology criteria [18]. Infusions with infliximab were given at weeks 
0, 2, 6 and 14 weeks and from thereon every 8 weeks. Generally, infliximab was given 
in combination with stable doses of methotrexate. Infliximab was administered 
intravenously in a starting dose of 3 mg/kg. In patients with inadequate response 
as judged by the patients’ rheumatologist the dose of infliximab could be increased 
to 7.5 mg/kg. Blood samples (nonfasting) were collected in the morning, prior to 
each infusion on week 0, 6, 22 and 48 and were stored at -70 °C until analyses. Total 
cholesterol, HDL-cholesterol, triglycerides, apo A-1 and apo B concentrations were 
measured and the total / HDL-cholesterol and apo B / apo A-1 ratios were calculated. 
At each visit disease activity, defined as DAS-28 [19] and drug treatment was assessed. 
In total, 108 patients were included in the cohort, but 28 patients dropped out in the 
first year of treatment: 22 because of non-response (78.5%), 5 because of side effects 
(18%) and 1 patient (3.5%) who died owing to infliximab-unrelated events. Thus, the 
data from 108 patients were eligible for analyses. The baseline characteristics of the 
dropout patients were comparable to those of the patients included in the study (data 
not shown). Thus, all included patients completed the study period of 48 weeks and 
the patients who dropped out (n=28) were not included for the analysis. There were 
no (additional) exclusion criteria. 
Lipids
Total serum cholesterol (N < 5.0 mmol/l (193 mg/dl)) and triglycerides (N < 2.2 
mmol/l, 196 mg/dl)) were measured by an enzymatic method using Roche clinical 
chemistry analyzers. HDL-cholesterol (N men > 0.9 mmol/l (35 mg/dl), women > 1.1 
mmol/l (42 mg/dl)) was determined enzymatically with PEG-modified enzymes. The 
atherogenic index was calculated using the following formula: atherogenic index = total 
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/ HDL-cholesterol. Apo A-1 (N men 1.04-2.02 g/l, women 1.08-2.25 g/l) and apo B (N 
men 0.66-1.33 g/l, women 0.60-1.17 g/l) were analyzed by an immunoturbidimetric 
method, using assays supplied by Roche Diagnostics.
As it was expected that only small differences in the concentration of analyses could 
be significant, collected sera were first stored frozen and subsequently analyzed on 
the same day in a single run with all sera belonging to one person grouped together. 
This set-up produces within group analytical coefficients of variation for the analyses 
in their reference range of less than 1%.
Statistical analyses
As some patients were treated with prednisone, differences in lipid profiles between 
prednisone users (yes/no) were analyzed by using independent t-tests for normally 
distributed variables (i.e. HDL-cholesterol, apo A-1, apo B, and the apo B / apo A-1 
ratio), and Mann Whitney U tests were used for not normally distributed variables 
(i.e. total cholesterol, atherogenic index and triglycerides). 
The time course of lipid levels during treatment with infliximab was investigated by 
using general estimation equations (GEEs). This regression technique is used as it 
adjust for dependency of several measurements within one subject and is capable of 
dealing with unequally spaced time intervals and with missing data [20]. For these 
analyses each lipid value was included separately as dependent variable and time was 
included as a categorical independent variable. 
GEE analyses were also used to investigate the influence of indicators of disease 
activity (i.e. DAS-28 score and CRP) and prednisone dose on all lipid levels. For this 
we performed two analyses: (1) GEE analyses including a lipid value and an indicator 
of disease activity or prednisone dose; for example total cholesterol as dependent 
variable and DAS-28 as independent variable, total cholesterol as dependent variable 
and CRP as independent variable and total cholesterol as dependent variable and 
prednisone as independent variable; (2) GEE analyses including a lipid value and an 
indicator of disease activity corrected for prednisone dose. With GEE analyses the 
whole development of a certain lipid is associated with the development of disease 
activity or prednisone dose resulting in one regression coefficient. All analyses were 
adjusted for age and gender. As the distribution of total cholesterol, atherogenic index 
and triglycerides were not normal, a log transformation was performed before the 
GEE analyses. All analyses were performed with STATA (version 7) and p-values of 
less than 0.05 were considered statistically significant [21]. 
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RESULTS
Patients
The study population consisted of 80 (62 women and 18 men) consecutively included 
RA patients with a mean age of 56 years (SD 14 years). The median disease duration 
was 10 years (range: 0–59 years), 55 patients (69%) were IgM-Rheumatoid factor 
positive and 67 patients (82%) had erosions. At baseline statins were used by 4 patients 
and 2 patients (2%) reported diabetes mellitus. During the study period none of the 
included patients started statins or glucose lowering therapy. Seventy-seven patients 
(96%) used concomitant methotrexate in a stable dose, i.e. 15 mg/wk at all time points 
and 35 patients (44%) used prednisone at the start of the study (mean prednisone 
dose 8.3 mg/day). As expected treatment with infliximab leads to a significantly better 
DAS-28-score at 48 weeks compared to baseline: 5.7 vs 3.9 (p<0.01).
Lipids
The course of lipid levels over time during treatment with infliximab is shown in Table 
1. Patients who used prednisone had higher total- and HDL-cholesterol levels and 
a lower atherogenic index at baseline, but these differences did not reach statistical 
significance. 
After six weeks infliximab treatment total cholesterol levels increased by 6.1% (p<0.01) 
and HDL-cholesterol levels increased by 10.3% (p<0.01), resulting in a 6.4% decrease 
of the atherogenic index (p<0.01). In the next period (6 to 22 weeks) both total- and 
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Table 1 Total cholesterol, HDL-cholesterol, triglycerides (mmol/l), Apo A-1, Apo B (g/l) and 
the atherogenic index and apo B/apo A-1 ratio during treatment with infliximab
* p<0.05 compared to baseline (performed by GEE analyses).
Variable Baseline 6 weeks 22 weeks 48 weeks
Total cholesterol (mmol/l), 
median (range)
4.79 (2.70–8.10) 5.08 (2.79–9.18)* 4.94 (2.90–10.42)* 4.81 (3.21–7.29)
HDL-cholesterol (mmol/l), mean 
(SD)
1.46 (0.50) 1.61 (0.54)* 1.55 (0.53)* 1.53 (0.51)
Atherogenic Index, median 
(range)
3.42 (1.74–7.78) 3.20 (1.59–8.63)* 3.43 (1.67–8.08) 3.38 (1.62–10.70)
Triglycerides (mmol/l), median 
(range)
1.26 (0.62–4.40) 1.39 (0.52–3.80)* 1.32 (0.46–3.36) 1.26 (0.62–3.48)
Apo A-1 (g/l), mean (SD) 1.58 (0.35) 1.70 (0.33)* 1.65 (0.33)* 1.65 (0.33)*
Apo B (g/l), mean (SD) 0.93 (0.23) 0.95 (0.24) 0.94 (0.24) 0.93 (0.19)
Apo B / Apo A-1 ratio (SD) 0.62 (0.20) 0.58 (0.20)* 0.59 (0.18) 0.59 (0.16)
Changes in lipid profileChapter 4B
HDL-cholesterol levels decreased, but remained significantly elevated compared to 
baseline. At 48 weeks, total- and HDL-cholesterol levels approached baseline levels. 
As total- and HDL-cholesterol levels moved towards baseline levels the atherogenic 
index revealed no significant difference compared to the baseline index at 22 and 48 
weeks. Triglycerides levels did not change during the whole treatment period. 
Compared to baseline apo A-1 levels increased 4.5% at 48 weeks (p<0.01), whereas 
apo B levels and the apo B / apo A-1 ratio did not change significantly at 48 weeks 
compared to baseline. 
Lipids and disease activity
The course of lipids over time was compared to the course of disease activity after 
adjustment for age and gender. GEE analyses yielded a significant inverse association 
between disease activity and lipid levels (Table 2). Changes in disease activity (DAS-28) 
were significantly related with changes in HDL- as well as total cholesterol levels. This 
means that if disease activity according to DAS-28 decreases one point, total cholesterol 
will raise 0.016 mmol/l (0.618 mg/dl) and HDL-cholesterol will raise 0.045 mmol/l 
(1.737 mg/dl), resulting in a more favorable i.e. lower, atherogenic index. Similarly, the 
individual inflammation parameter CRP was significantly inversely associated with 
both HDL- and total cholesterol levels. Moreover, the analyses showed that disease 
activity was inversely related with apo A-1, resulting in a lower, i.e. more favorable, 
apo B / apoA-1 ratio.   
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Table 2 Relationship between lipid items, indicators of disease activity and prednisone
Regression coefficients and standard errors estimated by GEE analyses for each lipid item as a continuous outcome 
variable. Atherogenic index, Total cholesterol (mmol/l), HDL-cholesterol (mmol/l), Apo B / Apo A-1 ratio, Apo A-1 
(g/l) and Apo B (g/l). All analyses were adjusted for age and gender. * p<0.05.
 Atherogenic index Total cholesterol HDL-cholesterol
Variable Coefficient (SE) Coefficient (SE) Coefficient (SE)
Indicators of disease activity    
1-point decrease/difference of DAS-28 -0.016 (0.008)* 0.016 (0.005)* 0.045 (0.013)*
10-points decrease/difference of CRP -0.026 (0.001)* 0.024 (0.001)* 0.067 (0.001)*
Reduction/difference of 1 mg prednisone 0.009 (0.004)* -0.004 (0.002)* -0.016 (0.006)*
 Apo B / Apo A-1 Apo B Apo A-1
Variable Coefficient (SE) Coefficient (SE) Coefficient (SE)
Indicators of disease activity    
1-point decrease/difference of DAS-28 -0.013 (0.005)* 0.004 (0.004) 0.036 (0.009)*
10-points decrease/difference of CRP -0.014 (0.001)* 0.009 (0.001) 0.045 (0.001)*
Reduction/difference of 1 mg prednisone 0.005 (0.002)* 0.001 (0.002) -0.009 (0.004)*
Lipids and prednisone
During treatment with infliximab lipid levels were compared to changes in prednisone 
dose at different time points after adjustment for age and gender. Changes in prednisone 
dose were related to changes in HDL- and total cholesterol (Table 2). Prednisone 
changes, however, had a greater influence on HDL- than on total cholesterol levels 
resulting in an inverse association between prednisone dose and the atherogenic 
index. In other words, a higher prednisone dose is associated with a lower, i.e. more 
favorable atherogenic index. Furthermore, the prednisone dose appeared to have a 
significant positive relation with apo A-1, leading to a significant inverse association 
with the apo B to apo A-1 ratio. 
The reported associations between lipids and disease activity and between lipids and 
prednisone did not change when prednisone and disease activity parameters were both 
included as independent variables in the same regression analysis (data not shown).  
Due to the favourable effect of infliximab on the DAS-28 score, the prednisone dose 
was gradually decreased from a median dose of 8.3 to 4.6 mg/day. Subgroup analysis 
revealed no significant differences with regard to cholesterol levels between RA patients 
with prednisone and without prednisone at all time points.
DISCUSSION
In this study we observed a significant increase of total- and HDL-cholesterol levels 
after 6 weeks of infliximab treatment, which gradually returned to baseline after 48 
weeks. As a result improvement of the atherogenic index at six weeks was not observed 
anymore from 22 weeks onwards. Longitudinal data analyses, i.e. GEE analyses, 
revealed that lowering the prednisone dose attenuated the effects of infliximab on 
total cholesterol and HDL-cholesterol levels and its main protein part apo A-1, thereby 
abolishing the improvement of the atherogenic index as well as the apo B to apo A-1 
ratio. Nevertheless, apo A-1 levels remained significantly elevated after 48 weeks of 
treatment. This latter might be important as there is accumulating epidemiological 
evidence indicating that high levels of apo A-1 are strongly related with a lower risk 
for future CVD [5, 6]. 
Recent research has shown that systemic inflammation plays a pivotal role in the 
development of atherosclerosis. Immune cells dominate early atherosclerotic lesions, 
their effector molecules accelerate progression of the lesions and inflammation 
elicits CVD [22]. Hence, inflammation might be the key explaining the enhanced 
cardiovascular risk in RA patients [23]. Moreover, inflammation induces the acute 
phase response leading to lipid changes and alterations in lipoprotein metabolism. 
90
Changes in lipid profileChapter 4B
Most of these changes, i.e. decreased levels of HDL-cholesterol and apo A-1, are pro-
atherogenic and ultimately they may contribute to the increased cardiovascular risk in 
RA. In this study, a decreasing disease activity resulted in a lower, atherogenic index as 
a result of higher total cholesterol levels and even more pronounced higher HDL-levels. 
In addition, a decrease of disease activity led to a better apo B to apo A-1 ratio, due 
to significantly increased apo A-1 levels. These findings are in line with other studies 
reporting an inverse association between inflammatory markers (ESR and CRP) and 
HDL-cholesterol or its apo A-1 [12, 13]. 
Differences reported in this study are small and may therefore question their clinical 
relevance. Several studies, however, illuminate the importance of lipid changes even 
though the observed differences are small. The Lipid Research Clinics Coronary 
Primary Prevention Trial (LRC-CPPT) as well as the Framingham Study for example 
show that a 0.026 mmol/l (1 mg/dl) increment of baseline HDL-cholesterol is associated 
with an approximately 3.5% risk reduction for coronary heart disease [24, 25]. Another 
study performed by Rubins et al. revealed that a 6% increase in HDL-cholesterol is 
associated with an absolute risk reduction of 4.4% of death from coronary heart disease 
or non-fatal infarction [26]. Although these findings cannot be directly extrapolated 
to our study, they demonstrate the clinical importance of only small lipid changes. 
Moreover several recent observations indicate that apo-B and apo A-1 may in fact be 
more powerful predictors of risk for CVD than the conventional lipid values [5, 6, 
22, 27]. This is important and might be clinically relevant as this study indicates that 
apo-A1 remains significantly elevated during the whole treatment period. 
Mechanisms underlying the decrease of HDL-cholesterol during inflammation are not 
firmly established. Our findings, however, suggest that alterations in prednisone dose 
are relevant. We showed that lowering the prednisone dose results in a decrease of total 
cholesterol levels, that is predominantly due to a decrease in HDL-cholesterol leading 
to a higher atherogenic index (as the effect on total cholesterol was less pronounced). 
Vice versa, increasing the prednisone dose might have favorable effects on the lipid 
profile. Nevertheless, it is highly uncertain whether or not this postulated beneficial 
effect is ultimately offset by other cardiovascular side effects of long-term prednisone 
use, as insulin resistance and hypertension. 
In addition to a previous study performed by our study group [14], the present study 
reveals additional insights into the influence of prednisone and disease activity on the 
lipid profile as both have a significant, but opposing, and more pronounced influence 
on HDL-cholesterol than on total cholesterol. 
Methotrexate may provide a substantial survival benefit, largely by reducing cardiovas-
cular mortality [28]. Patients in our investigation were on stable MTX doses during the 
treatment period. Hence, we were not able to evaluate the effect of MTX on the lipid 
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profile. Our results, however, do indicate that suppression of inflammation leads to a 
more favourable lipid profile which may also be conceivable for methotrexate.
There might be (additional) explanations for the observed longitudinal lipid 
changes. First, exercise increases HDL-cholesterol in healthy individuals [29] and 
immunosuppressive therapy is associated with a substantial clinical improvement 
whereby RA patients will increase their physical activity. Second, RA patients with a 
high disease activity have higher levels of tumour necrosis factor, which is associated 
with rheumatoid cachexia [30]. Treatment with infliximab obviously leads to lower 
levels of the tumour necrosis factor, therefore possibly leading to a better dietary intake 
resulting in increased lipid levels. Finally, we have to consider the possibility that 
the observed lipid changes are due to a direct effect of biologicals through blocking 
TNF-alpha. 
In conclusion, the present investigation shows that immunosuppressive therapy, 
with infliximab, might have beneficial effects on the increased cardiovascular risk in 
RA patients through several pathways: (1) due to its anti-inflammatory effects, (2) 
indirectly as a cause of lower prednisone doses, and (3) through, albeit small, anti-
atherogenic effect on the lipid profile. Prospective cardiovascular outcome studies are 
needed to establish whether or not immune-suppressive therapy indeed results in a 
lower cardiovascular risk. 
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ABSTRACT
Objective: To investigate the effect of treatment with infliximab on serum levels of 
Rheumatoid factor (IgM-RF), antibodies against cyclic citrullinated peptide (anti-CCP) 
and antibodies against deiminated human fibrinogen (ACF) and their association with 
disease activity and disease duration in patients with rheumatoid arthritis (RA).
Methods: The study sample included 62 consecutive patients who were treated with 
infliximab for at least one year. IgM-RF, anti-CCP and ACF were measured at 0, 14, 
30 and 46 weeks.
Results: Patients had a mean age of 54 years and median disease duration of 10 years 
and were predominantly female (95%). At baseline 63%, 77% and 82% of the patients 
were positive for IgM-RF, anti-CCP and ACF. In terms of percentages, the levels of 
IgM-RF were reduced by 64% at 46 weeks, while the anti-CCP and ACF levels were 
reduced by roughly 25%. The decrease in serum levels of these autoantibodies was not 
associated with the decrease in disease activity. The change in ACF was significantly 
related to disease duration, while the changes in IgM-RF or anti-CCP were not.
Conclusion: In conclusion, our study shows that in a cohort of RA patients who 
respond to infliximab therapy, all autoantibodies decreased significantly, but IgM-RF 
shows a larger decrease than anti-CCP or ACF. These changes in levels of autoantibodies 
are not directly related to the change in disease activity. Early in the disease ACF levels 
were best influenced by treatment with infliximab. 
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INTRODUCTION 
Rheumatoid arthritis is a chronic polyarticular inflammatory disease which may lead to 
cartilage destruction and bone erosions. One of the characteristics of the disease is the 
presence of autoantibodies. Rheumatoid factor (IgM-RF) is an antibody, which targets 
the Fc fragment of IgG. IgM-RF is observed in about 75% of the RA patients, but it is 
also frequently observed in other inflammatory diseases [1, 2]. Antibodies against cyclic 
citrullinated peptide (anti-CCP) target multiple citrullinated proteins and are highly 
specific for RA [3-5]. Antibodies against a specific citrullinated peptide, deiminated 
fibrinogen (ACF), previously described as filaggrin antibodies, are as sensitive and 
specific for RA as the anti-CCP antibodies [6]. Deiminated fibrinogen has been detected 
in inflamed joints of RA patients, but also in non-RA inflamed joints [6, 7]. This could 
suggest that the antibody response against deiminated fibrinogen, but not the target, is 
specific for RA. These findings and their presence in early and even preclinical disease 
[8] suggests a role for anti-CCP and ACF antibodies in the pathogenesis of RA. 
Furthermore, these antibodies (anti-CCP and ACF) appear to be a useful diagnostic 
tool and are predictive of disease progression and radiological damage [9]. Therefore, it 
is important to understand potential factors influencing these antibodies responses.
Several studies have described a decrease in IgM-RF serum level after disease modifying 
therapies [10-13]. Only few studies have examined the effect of aggressive RA treatment 
(anti-TNF) on the level of anti-CCP antibodies and these studies show conflicting 
results: 3 studies showed a decrease whereas 2 studies showed no change in anti-CCP 
titres during anti-TNF treatment [10-14].
Because of these conflicting results and to our knowledge the effect of treatment 
on serum levels of ACF antibodies has not been described, we investigated changes 
in IgM-RF, anti-CCP and ACF in a cohort of RA patients treated for one year with 
infliximab. 
PATIENTS AND METHODS 
Patients
Consecutive patients with RA, who were treated with infliximab for at least one year, 
were included. All patients fulfilled the ACR criteria for RA, had active disease (Disease 
Activity Score of 28 joints (DAS-28) ≥ 3.2) and had previously failed at least 2 DMARDs 
including methotrexate [15]. Previous infection with tuberculosis or cardiac failure 
NYHA class III and IV were contra-indications for treatment with infliximab. In total 
80 patients were included into the cohort, but 18 patients dropped out within the first 
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year of treatment; 13 because of non-response, 3 because of side effects, and 2 patients 
died due to infliximab unrelated events. Thus, 62 patients were eligible for analyses. 
The baseline characteristics of the drop-out patients were comparable to the patients 
included into the study (data not shown). 
Methods
Infusions with infliximab were given at 0, 2, 6 and 14 weeks and subsequently with 8 
weeks interval. Infliximab was administered intravenously in a starting dose of 3 mg/
kg. In patients with inadequate response as judged by the patient’s rheumatologist the 
dosage of infliximab could be increased to 7.5 mg/kg.
Demographic data
The demographic data collected at baseline were recorded from medical history and 
patient’s medical records. The following variables were collected: age, sex, disease 
duration, presence or absence of bony erosions, IgM-RF status (positive if IgM-RF > 30 
u/L), current and previous use of disease modifying anti-rheumatic drugs (DMARDs) 
and corticosteroids. The disease activity was measured at each visit using the DAS-28 
score [16]. 
IgM-RF, CCP and ACF
Serum was collected on the morning before each infusion and stored immediately at 
-20 ˚ C or lower until analyses. A total of 62 patients had serum available for evaluation. 
IgM-RF, anti-CCP and ACF were measured at 0, 14, 30 and 46 weeks.
The anti-CCP and IgM-RF was determined at the Jan van Breemen Institute, while 
the ACF was measured at Sanquin Research. IgM-RF was measured using an in-house 
ELISA. The anti-CCP level was measured using the anti-CCP-2 ELISA according to the 
manufacturer’s recommendations (Axis-Shield). The ACF was measured as described 
previously [17]. In summary, microtitre plates where incubated for 1 hr with 10 ug/ml 
in vitro deiminated fibrinogen at RT. After five washes with PBS/0.2% Tween, plates 
were incubated with serum samples diluted 1:50 in PBS, 0.05% (vol/vol)Tween-20, 0.2% 
Gelatine (PTG) and were incubated for one hour. All assays were done in duplicate. 
After 5 more washes plates were incubated with a horseradish peroxidase (HRP) 
labelled mouse monoclonal antibody to IgG for 1hr. The plates were developed with 
tetra methyl benzidine (TMB) in 0.11 M NaAc and H2O2 , and the reaction was stopped 
with H2SO4. The plates were read at 540 nm wavelength, samples were considered 
positive when above the cut-off value determined previously (150 AU/ml).
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Statistical analysis
In our analysis we only analyzed the positive patients for each test. Mann-Whitney test was 
used to compare changes in RF, anti-CCP and ACF between the different time-points. 
As the distributions of RF, anti-CCP and ACF were not normal, a log transformation 
before statistical analyses was performed. Subsequently, Generalized Estimating 
Equations (GEE) analyses were performed. GEE is a regression analysis for longitudinal 
data modulating the course of the independent variables and dependent variables over 
time. GEE was used to investigate the course of these autoantibodies over time during 
treatment with infliximab and their longitudinal relationship with disease activity; 
DAS, CRP and ESR and with disease duration. To analyse the influence the effect 
of disease duration on change in autoantibodies we calculated an interaction-term: 
disease-duration * time-point. These analyses were performed using STATA version 
7. A p-value of less than 0.05 was considered statistically significant. 
RESULTS
In total, 62 patients were included into the study: 59 (95%) women with a mean age 
of 54 years and median disease duration of 10 years (Table 1). The mean (SD) DAS-
28 decreased from 5.4 (1.3) to 3.7 (1.6) at 14 weeks and 3.6 (1.5) at 30 and 46 weeks. 
Median ESR (mm/hr) decreased from 27 (2–85) at baseline to 16 (3–105 at 46 weeks) 
and the median CRP (mg/ml) from 11 (0–175) at baseline to 5 (0–178) at 46 weeks.
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Table 1 Baseline characteristics of the 73 studied patients
Demography  
Age [years] Mean (SD) 54 (12)
Gender [female] n (%) 59 (81)
Disease duration [years] Median (range) 10 (1–49)
Erosive disease n (%) 57 (78)
Disease activity   
DAS-28 Mean (SD) 5.4 (1.3)
ESR [mm/hr] Median (range) 27.0 (2.0–85.0)
CRP [mg/l] Median (range) 11 (0.0–174.0)
Serum markers   
IgM-RF Median (range) 53 (5–804)
Positive n (%) 46 (63)
Anti-CCP Median (range) 500 (0–16,640)
Positive n (%) 56 (77)
ACF Median (range) 616 (63–13,463)
Positive n (%) 60 (82)
IgM-RF, anti-CCP and ACF
At baseline 63%, 77% and 82% of the patients were positive for IgM-RF, anti-CCP 
and ACF. All serum markers decreased significantly from baseline during one year 
treatment with infliximab as shown in Table 2. 
Lipids and disease activity
The course of lipids over time was compared to the course of disease activity after 
adjustment for age and gender. GEE analyses yielded a significant inverse association 
between disease activity and lipid levels (Table 2). Changes in disease activity (DAS-28) 
were significantly related with changes in HDL- as well as total cholesterol levels. This 
means that if disease activity according to DAS-28 decreases one point, total cholesterol 
will raise 0.016 mmol/l (0.618 mg/dl) and HDL-cholesterol will raise 0.045 mmol/l (1.737 
mg/dl), resulting in a more favorable i.e. lower, atherogenic index. Similarly, the individual 
inflammation parameter CRP was significantly inversely associated with both HDL- and 
total cholesterol levels. Moreover, the analyses showed that disease activity was inversely 
related with apo A-1, resulting in a lower, i.e. more favorable, apo B / apoA-1 ratio. 
In terms of percentages the levels of IgM-RF were reduced by 64 percent at 46 weeks 
and the anti-CCP and ACF levels were reduced by roughly 25% (Figure 1). The 
percentage decrease in IgM-RF was statistically greater than the decrease in anti-CCP 
and ACF (p<0.001).
Nineteen patients of the 39 patients (49%), who at baseline were positive for IgM-RF, 
had a negative IgM-RF titre at 46 weeks. Only one of the 47 anti-CCP positive patients 
(2%) and three of the 54 ACF positive patients (6%) had a negative titre at 46 weeks. 
The decrease in IgM-RF, anti-CCP and ACF levels during treatment with infliximab was 
compared to the course of the disease activity markers corrected for disease duration, 
gender and age: the analysis only showed a marginal association between ESR and 
anti-CCP levels, 1 mm/hr decrease in ESR is associated with a decrease of anti-CCP 
of 1.03 (SE 0.6) (p<0.05). We could not establish any other relationship between any 
of the disease activity markers and autoantibody levels.
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Table 2 Changes in IgM-RF, anti-CCP and ACF during one year treatment with infliximab
* p<0.001 vs. baseline calculated using GEE.
 Baseline 14 weeks 30 weeks 46 weeks
IgM-RF 110 (34–804) 62 (13–627) * 51 (7–490) * 38 (8–465)*
Anti-CCP 1,232 (83–16,640) 1,220 (42–10,500) 1,050 (26–12,920)* 960 (30–11,880)*
ACF 754 (63–13,463) 687 (66–13,097) * 652 (69–10,289)* 539 (58–13,783)*
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Likewise we also compared the course of autoantibodies corrected for disease duration. 
This analysis showed that the change in ACF was significantly related to disease 
duration but neither to IgM-RF nor anti-CCP. Interestingly, the ACF decreased more 
in patients with shorter disease duration (p<0.05).  
DISCUSSION
In this study of RA patients who received infliximab for one year, IgM-RF, anti-CCP and 
ACF levels all decreased significantly. The decrease in IgM-RF was substantially larger 
than anti-CCP and ACF. Moreover, almost 50 percent of the IgM-RF positive patients 
at baseline turned negative during treatment with infliximab, while seroconversion of 
anti-CCP and ACF occurs in less than 10%.
The finding that anti-CCP decreases in our study differs from two other studies who 
reported unchanged anti-CCP levels during anti-TNF treatment. This difference 
could be due to the fact that we studied patients from a cohort of RA patients treated 
with infliximab for at least one year: these patients can all be classified as responders. 
Other studies observing responders showed a decrease in anti-CCP levels or showed 
a decrease in their responder subgroup [10, 12, 14]. On the other hand, studies 
investigating both responders and non-responders found no significant changes in 
anti-CCP [13]. 
Remarkably, we did not find a direct relationship between disease activity and 
changes in levels of autoantibodies, except a marginal relationship between ESR and 
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Figure 1 Percentage change from baseline in serum levels of IgM-RF, anti-CCP and ACF 
at 0, 14, 30 and 46 weeks during one year treatment with infliximab.
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anti-CCP. This was surprising as the course of disease activity paralleled the change 
in autoantibodies. However, earlier studies investigating the effect of anti-rheumatic 
treatment on autoantibody titres, could not establish a consistent relationship between 
disease activity and changes in IgM-RF or anti-CCP [10, 14]. An explanation could be 
that autoantibody levels decrease in patients who respond to anti-rheumatic therapy, 
but there is no direct relationship with disease activity [10, 12, 15]. The effects of 
anti-TNF treatment in RA have been attributed to the induction of apoptosis of 
inflammatory cells [17]. Citrullination is a post-translational modification of proteins 
in the apoptotic process and therefore infliximab could influence the formation and 
presence of antibodies against citrullinated proteins by directly interfering with the 
regulation of the apoptotic process.
To our knowledge, this study was the first to investigate the response of ACF levels 
during treatment with a TNF-blocking agent. The ACF concentration showed a 
significant decrease during treatment with infliximab. ACF levels also decreased more 
in patients with shorter disease duration, possibly implying a window of opportunity 
for the treatment of RA. Antibodies to deiminated (citrullinated) fibrinogen have 
been implicated as a pathogenic factor for RA because of their high specificity, their 
presence in preclinical disease [18]. and their presence in rheumatoid synovium [7]. 
Lowering ACF levels through anti-rheumatic treatment may cause a disruption of the 
vicious circle of the proposed immunological conflict between citrullinated fibrin and 
its antibodies leading to self maintenance of RA synovitis [5].
In summary, our study shows that in a cohort of RA patients responding to infliximab 
treatment during one year of therapy, IgM-RF shows a larger decrease than anti-CCP 
or ACF, but all three autoantibodies decrease significantly. This decrease is not directly 
related to the change in disease activity but probably indirectly to a good clinical response. 
Early in the disease ACF levels were best influenced by treatment with infliximab. 
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ABSTRACT
Objective: Treatment of patients with infliximab, a chimeric monoclonal IgG1 antibody 
against tumor necrosis factor, may result in the formation of infliximab-specific IgG 
antibodies. This study evaluated the clinical significance of these antibodies in patients 
with rheumatoid arthritis (RA).
Methods: Anti-infliximab antibodies were measured using a newly developed radioim-
munoassay in a cohort of 51 consecutive patients with RA treated with infliximab, 
with a follow-up of 1 year. In addition, serum infliximab levels were determined by 
enzyme-linked immunosorbent assay. The results were analyzed in relation to the 
clinical response to treatment according to the European League Against Rheumatism 
criteria.
Results: Antibodies against infliximab were detected in 22 patients (43%). Patients 
without detectable anti-infliximab antibodies (n=29 [57%]) were significantly more 
often classified as responders (20 of 29 [69%]) compared with patients with detectable 
anti-infliximab antibodies (8 of 22 [36%]; p=0.04). Three patients had an infusion-
related allergic reaction, all of whom had detectable anti-infliximab antibodies.
Conclusion: In this study, nearly half of the RA patients treated with infliximab 
developed anti-infliximab antibodies within the first year of treatment. This seems to 
be clinically relevant, since development of anti-infliximab antibodies is associated 
with a reduced response to treatment. 
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INTRODUCTION 
Treatment with infliximab provides great benefit to many patients with rheumatoid 
arthritis (RA) [1-3]. However, some patients have persistent active disease and others 
show loss of efficacy after prolonged treatment. Infliximab can induce the formation of 
antibodies to infliximab that may lead to side effects and loss of efficacy. Development 
of antibodies to infliximab is related to the dose of infliximab and is diminished by 
concomitant treatment with methotrexate (MTX) [1]. To what extent formation of 
antibodies to infliximab plays a role in clinical practice is unknown.
The Anti–Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant 
Therapy (ATTRACT) study group reported that 8% of patients receiving infliximab 
plus MTX developed antibodies to infliximab during the 102-week study period of 
the trial. However, despite the presence of antibodies, similar proportions of patients 
with antibodies to infliximab and without antibodies to infliximab achieved a 20% 
improvement response according to the American College of Rheumatology response 
criteria (ACR20) [4]. We have recently shown that a good response to treatment is 
associated with high serum trough levels of infliximab [5]. Conversely, serum trough 
levels of infliximab were below the limit of detection in patients prior to development of 
infusion-related allergic reactions. These findings suggest that formation of antibodies 
against infliximab might play a role in the efficacy of infliximab therapy in patients 
with RA.
To investigate the formation of antibodies against infliximab, we developed an antigen 
binding assay and measured levels of anti-infliximab antibodies in the serum of a cohort 
of 51 RA patients treated with infliximab, with a follow-up of 1 year. The presence of 
anti-infliximab IgG antibodies as well as levels of infliximab in the serum were related 
to clinical response and allergic reactions. 
PATIENTS AND METHODS 
Patients
Consecutive patients with RA who were receiving infliximab for RA at the Department 
of Rheumatology of Slotervaart Hospital in Amsterdam, The Netherlands, from April 
2000 to January 2002 were included in this open, prospective observational study. 
Treatment of these patients was in accordance with the consensus statement on the 
initiation and continuation of tumor necrosis factor (TNF)-blocking therapy in RA [6]. 
All patients fulfilled the American College of Rheumatology (formerly, the American 
Rheumatism Association) 1987 revised criteria for RA [7], and all had evidence of 
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active disease, as indicated by a Disease Activity Score in 28 joints (DAS-28) of >3.2 
despite earlier treatment with 2 disease-modifying antirheumatic drugs (DMARDs), 
including MTX, at a dosage of 25 mg weekly or at the maximum tolerable dosage 
(based on the Dutch guidelines for starting anti-TNF treatment).
All patients were given intravenous infusions of 3 mg/kg of infliximab at weeks 0, 2, and 
6, and every 8 weeks thereafter. After 14 weeks of treatment, the treating rheumatologist 
was free to increase the dosage of infliximab to 7.5 mg/kg body weight in patients 
whose condition exhibited an inadequate response. Moreover, after 14 weeks, dosing 
intervals were kept stable at 8-week intervals. Concomitant medication, including 
MTX, was continued.
Disease activity was assessed using the DAS-28 [8] before each infusion. For assessment 
of clinical response, we used the European League Against Rheumatism (EULAR) 
response criteria [9]. Patients who stopped treatment or who needed a dosage escalation 
were regarded as non-responders. An infusion reaction was defined as any significant 
adverse event that occurred during the infusion or within 2 hours after the infusion. 
Measurement of serum infliximab and anti-infliximab antibody levels
Serum samples were collected 1 hour prior to each infusion, for the assessment of 
serum infliximab and anti-infliximab antibodies. Infliximab levels in the serum were 
determined by enzyme-linked immunosorbent assay, as described elsewhere [5]. Anti-
infliximab was detected with a newly developed radioimmunoassay. Infliximab-specific 
IgG was measured by an antigen binding test, essentially according to the procedure 
described by Aalberse et al. [10]. Briefly, serum (1 μl/test) was preincubated with 
agarose-immobilized protein A (1 mg/test; Pharmacia, Uppsala, Sweden) in Freeze 
buffer (CLB Sanquin, Amsterdam, The Netherlands). Non-bound serum components 
were removed by washing before ~1ng of 125I-labeled pepsin-treated infliximab 
was added. After overnight incubation, non-bound radiolabel was washed away and 
agarose-bound radioactivity was measured. High-radioactivity samples were retested 
at the appropriate dilutions. Test results were converted into arbitrary units (AU) per 
milliliter by comparison with dilutions of a reference serum. The cutoff level for a 
positive signal was set at 12 AU (mean +3 SD of the pretreatment values).
Statistical analysis
Differences between patient groups were analyzed by chi-square test or Mann-Whitney 
U test, as appropriate. The threshold for significance was set at a p-value of less than 
0.05. To analyze the change in the DAS-28 among patients with and without anti-
infliximab antibodies after 1 year of treatment, we used the last observation carried 
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forward for patients who stopped treatment or who had received an increased dosage 
of infliximab.
RESULTS
Characteristics of the cohort
The majority of the 51 patients who entered the study were women (82%). The mean 
± SD age of the patients was 56 ± 13 years and the mean ± SD disease duration was 
12 ± 9 years. Seventy percent of the patients were rheumatoid factor positive. The 
mean number of DMARDs received before infliximab treatment was 3.7. Forty-four 
patients (86%) were receiving concomitant MTX, with a mean dosage of 15 mg/
every week, while 3 patients were receiving azathioprine and 1 patient was receiving 
concomitant cyclosporine. The remaining 3 patients were not taking concomitant 
immunosuppressive drugs. At study entry, all patients had active disease, as indicated 
by a mean ± SD DAS-28 of 6.0 ± 1.3.
Clinical response
After 1 year of follow-up, 28 patients (55%) were classified as treatment responders 
according to the EULAR response criteria, without having needed an increase in the 
infliximab dosage. After 14 weeks of treatment, the mean ± SD DAS-28 had improved 
to 4.7 ± 1.7. Eight patients stopped treatment before the end of 1 year of therapy. Two 
patients stopped receiving infliximab after developing an infusion-related allergic 
reaction. Two patients stopped treatment because of skin problems, 1 patient because 
of edema, and 3 patients because of treatment inefficacy. Six patients received a dosage 
escalation. 
Detection of anti-infliximab antibodies
Prior to treatment, the anti-infliximab concentration was below 10 AU/ml in all 51 
samples. At follow-up, serum samples from 22 patients were found to be positive for 
anti-infliximab antibodies. One patient was antibody positive at week 6 after start 
of treatment, 6 patients at week 14, 6 patients at week 22, 2 patients at week 30, 4 
patients at week 38, and 3 patients at week 46. In most of these patients, the titer of 
anti-infliximab antibodies increased during continuation of treatment. In 5 patients 
with relatively low titers of anti-infliximab (25 AU/ml, 93 AU/ml, 18 AU/ml, 25 AU/
ml, and 64 AU/ml), the anti-infliximab levels became undetectable during follow-up, 
while in 3 patients, anti-infliximab antibodies fell below the level of detection after 
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dosage escalation. In these latter 3 patients, we observed an increase in the serum trough 
levels of infliximab just above the limit of detection (0.1 mg/liter) that coincided with 
an improvement in the DAS-28.
Patients without detectable anti-infliximab antibodies were significantly more often 
classified as responders when compared with patients with detectable anti-infliximab 
antibodies (20 of 29 without antibodies [69%] versus 8 of 22 with antibodies [36%] 
considered responders; p=0.04) (Figure 1). Patients without detectable anti-infliximab 
antibodies had significantly more improvement in the DAS-28 than did patients with 
detectable anti-infliximab antibodies (mean ± SD decrease in the DAS-28 1.9 ± 1.2 
versus 0.9 ± 1.8; p=0.02). The maximum anti-infliximab titer was significantly higher 
in patients classified as non-responders (median 42 AU/ml, interquartile range 8–310 
AU/ml) compared with patients classified as responders (median 9 AU/ml, interquartile 
range 6–17 AU/ml) (p=0.025) (Figure 2).
In 3 patients, there was an infusion-related allergic reaction. In all 3 of these patients, 
the infusion reactions consisted of tachycardia, erythema, and shortness of breath. 
These patients were treated with antihistamines, and full recovery occurred within 
a few hours. Two of the patients stopped further treatment, whereas 1 patient 
continued treatment without further infusion reactions. Anti-infliximab antibodies 
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Figure 1 Presence or absence of detectable anti-infliximab antibodies in relation to 
response to treatment (according to the European League Against Rheumatism criteria) 
with infliximab. Patients without detectable anti-infliximab were significantly more often 
classified as responders compared with patients with detectable anti-infliximab (20 of 29 
[69%] versus 8 of 22 [36%]; p=0.04).
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were detected in the serum of all 3 of these patients (786 AU/ml, 748 AU/ml, and 64 
AU/ml, respectively). However, most of the patients with anti-infliximab antibodies, 
including 2 patients with the highest titers of anti-infliximab (1,359 AU/ml and 29,133 
AU/ml), did not develop an allergic infusion reaction.
The development of anti-infliximab antibodies coincided with a decrease in serum 
trough levels of infliximab prior to the detection of anti-infliximab. Detection of 
antibodies against infliximab occurred only in samples with undetectable serum trough 
levels of infliximab. An example is shown in Figure 3. Mean serum trough levels of 
infliximab at 8 weeks after administration of 3 mg/kg infliximab were significantly 
lower in patients with anti-infliximab antibodies compared with patients without such 
antibodies (0.2 mg/liter versus 1.5 mg/liter; p<0.001).  
Baseline characteristics of the patients with and without anti-infliximab antibodies were 
similar. The mean MTX dose in patients with and without anti-infliximab antibodies 
was similar. None of the 3 patients receiving azathioprine as concomitant therapy 
had detectable anti-infliximab antibodies. Antibodies to infliximab were detected in 
2 of the 3 patients who did not receive concomitant medication. All of these patients 
who had not taken concomitant medication were considered non-responders to the 
infliximab regimen.
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Figure 2 Maximum anti-infliximab titers in patients classified as responders versus patients 
classified as non-responders to infliximab therapy. The maximum anti-infliximab titer was 
significantly higher in non-responders (median 42 arbitrary units [AU]/ml, interquartile range 
8–310) compared with responders (median 9 AU/ml, interquartile range 6–17) (p=0.025). 
Data are presented as box plots, where the boxes represent the 25th to 75th percentiles, 
the lines within the boxes represent the median, and the lines outside the boxes represent 
the 10th and 90th percentiles.
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DISCUSSION
The results presented herein show that almost half of the 51 patients with RA who were 
treated with 3 mg/kg infliximab every 8 weeks developed detectable anti-infliximab 
IgG antibodies within the first year of treatment. Moreover, the presence of these 
antibodies was associated with a reduced response to treatment.
In the ATTRACT study, 8% of patients receiving infliximab plus MTX developed 
antibodies to infliximab during the 102-week study period. It was reported that despite 
the presence of antibodies, similar proportions of patients with antibodies to infliximab 
and without antibodies to infliximab achieved an ACR20 response [2]. In patients with 
Crohn’s disease, 61% of patients treated with infliximab developed anti-infliximab 
antibodies [11]. It has been demonstrated that RA patients who respond to therapy have 
higher serum trough levels of infliximab compared with patients who do not respond to 
therapy [5]. Indeed, serum trough levels of infliximab were undetectable after an 8-week 
treatment interval in patients who developed an infusion-related allergic reaction.
The difference between the findings of this study and those reported by the ATTRACT study 
group might be explained by the fact that in our study, all patients started treatment on the 
3 mg/kg dosage every 8 weeks, while 75% of the patients in the ATTRACT study received 
higher dosages. In addition, some of the difference might be attributable to differences in 
the assays used; thus, a formal comparison between the assays is warranted.
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Figure 3 Trough levels of infliximab in the serum (□), levels of anti-infliximab (  ), and the 
Disease Activity Score in 28 joints (DAS-28) (○) in a rheumatoid arthritis patient treated 
with infliximab. After an initial improvement of disease activity, the patient had a relapse 
of disease activity that coincided with a decrease in the serum trough levels of infliximab 
and an increase in the anti-infliximab titer. AU, arbitrary units.
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Experiments with animal models have shown that induction of an immune response 
to therapeutic antibodies is associated with an accelerated clearance of the antibody 
[12]. Patients with detectable anti-infliximab have lower mean serum trough levels of 
infliximab compared with patients without anti-infliximab antibodies. This indicates 
that anti-infliximab antibody formation accelerates the clearance of infliximab from 
the circulation.
Interestingly, we observed that in some patients with anti-infliximab antibodies and 
an inadequate response to treatment, continuation of treatment with higher dosages 
of infliximab resulted in decreased levels of anti-infliximab antibodies. This might 
be attributable to induction of immune tolerance, similar to what is seen in patients 
with hemophilia who develop antibodies to factor VIII. Alternatively, it could be the 
result of overdosing the capacity of the immune system to produce anti-infliximab 
antibodies. It can be speculated that continuation of treatment with increased dosages 
of infliximab is effective in patients with low anti-infliximab antibody titers, whereas 
those patients with high titers of anti-infliximab antibodies probably benefit more 
from switching to other TNF-blocking agents.
Infliximab may induce infusion-related allergic reactions. In all 3 patients who 
developed an infusion-related reaction, high levels of anti-infliximab antibodies were 
detected. It is remarkable that most of the patients with anti-infliximab antibodies did 
not have a clinically overt allergic response. This is not simply related to the titer of the 
antibodies, since 2 patients who had the highest antibody titers did not have clinically 
overt infusion reactions. The fact that 2 of the 3 patients who received infliximab 
without concomitant immunosuppressive medication developed anti-infliximab 
antibodies illustrates the importance of adequate concomitant immunosuppressive 
therapy to prevent formation of antibodies to infliximab.
Many patients with RA exhibit persistent disease activity despite having received 
infusions of infliximab. The response to infliximab therapy is related to the level of 
infliximab in the serum and the presence of anti-infliximab antibodies, and shows 
a large interindividual variation. Further investigation into the mechanisms that 
determine serum concentrations of infliximab and formation of anti-infliximab 
antibodies may help to optimize this treatment. 
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Chapter 7
INTRODUCTION 
Infliximab is highly effective and relatively safe for the treatment of patients with 
rheumatoid arthritis (RA) in clinical trials [1-5]. This prospective cohort study was 
undertaken to determine adverse events, in particular, infections in patients with RA 
treated with infliximab in daily clinical practice. 
METHODS AND RESULTS
We treated 168 patients with RA between 1 April 2000 and 1 October 2002, 82% female, 
with a median disease duration of 10 years (range 1–49). Inclusion criteria were 28 joint 
count Disease Activity Score (DAS-28) of >3.5 and failure of two disease modifying 
antirheumatic drugs, including methotrexate. Patients with heart failure or with a 
malignancy 5 years before screening were excluded. After the alert about tuberculosis, 
6 patients starting with infliximab treatment were screened for that disease. 
All patients were treated with an initial infliximab dose of 3 mg/kg (weeks 0, 2, 6, and 
subsequently, every 8 weeks). When the response was insufficient — that is, a decrease 
in DAS-28 <1.2 compared with baseline on two subsequent occasions, the dose could 
be increased to 7.5 mg/kg. The median duration of treatment was 0.86 years (range 
0–2.5); the median number of infusions used was 7 (range 1–18). Methotrexate and 
prednisone were used by 92% and 50% of the patients, respectively.
Patients were systematically asked about events and, explicitly, about infections at each 
visit. All events occurring during the infliximab treatment period were interpreted 
as adverse events. 
The most common mild adverse event was short lived headache. Early allergic 
reactions were seen in 12 patients (0.08/patient year), but none developed severe 
cardiopulmonary problems. Some cases of heart failure (n = 2), neuropathy (n = 1), 
and malignancy (n = 2) were observed. Two patients died during the study, one of a 
cerebrovascular accident and one of unknown cause.
Patients frequently (43–57%, depending on the definition used) had infections, most 
commonly from the upper respiratory tract and the lower urinary tract (Table 1). One 
case of tuberculosis was seen. The number of clinically important infections was 0.59/
patient year, whereas serious infections were found in 0.08/patient year.
Compared with patients receiving low dose infliximab, significantly (p<0.05) more 
patients with the increased dose had clinically important infections (including 
serious infections), but other adverse events, demographic characteristics, and drug 
use between the groups were comparable. After correction for treatment duration 
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with infliximab, the rate of clinical infections was significantly higher in the group 
receiving the increased dose. However, after correction for treatment duration, clinically 
important infections were not significantly more common in the group receiving the 
increased dose.
DISCUSSION
Our study has shown that infection is the most common adverse event of infliximab 
treatment in daily practice. Clinical infections and clinically important infections were 
found more frequently in patients receiving high dose infliximab, without proven 
causality. 
The occurrence of infections in our study is in the same range as that described 
in (randomised) clinical trials of infliximab [1, 3, 5, 7]. However, the incidence of 
infection in our study was much higher than those described in a population based 
study of patients with RA not treated with infliximab, 64 versus 32 events per patient 
per year [8].
There is evidence that a higher risk for infections occurs with a higher RA activity 
[9]. It is reasonable to suppose that patients with a dose increase had greater disease 
activity than those treated with only low dose infliximab. We are unable to comment 
on whether the higher incidence of infections is associated with a high disease activity 
or with the strong immunosuppressive action of infliximab, or both. 
In conclusion, infliximab can be used safely in daily clinical practice, but both doctors 
and patients should be aware of the (infection) risks, especially in patients receiving 
a higher dose (>3 mg/kg) of infliximab, in order to anticipate and minimise these 
risks. 
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Chapter 8
ABSTRACT
Intravenous pamidronate is frequently used for the treatment of osteoporosis in patients 
who cannot tolerate oral bisphosphonates. The aim of the present study was to compare 
the changes in bone mineral density (BMD) after 1 year of treatment with either oral 
alendronate or intravenous pamidronate in patients with osteoporosis. We studied 40 
consecutive patients starting treatment for osteoporosis: 20 received oral alendronate 
10 mg/day and 20 received intravenous pamidronate 60 mg/3 months. Patients were 
started on intravenous pamidronate in the case of intolerance (within 1 month of 
start of treatment) of an oral bisphosphonate or in the case of contraindications for 
an oral bisphosphonate. BMD (spine and total hip) was measured with dual X-ray 
absorptiometry (DEXA) at the start of treatment and after 1 year. The BMD of the 
lumbar spine increased by 4.0% (p<0.05 vs baseline) in both groups, and the BMD 
of the hip increased by 3.3% and 2.9% (p<0.05 vs baseline) in the alendronate and 
pamidronate groups, respectively. The increases in BMD of the vertebral spine and 
the total hip after 1 year are comparable in the alendronate and pamidronate groups. 
We conclude that intravenous pamidronate can be used successfully as an alternative 
treatment in patients with gastrointestinal intolerance of an oral bisphosphonate. 
122
Effect pamidronate versus alendronate on BMDChapter 8
INTRODUCTION 
Osteoporosis is a systemic bone disease characterized by loss of bone mineral density 
(BMD) and deterioration of micro-architecture. This results in fragile bones with an 
increased risk of fractures [1].
Bisphosphonates are the most frequently used drugs for the treatment and prevention 
of osteoporosis. These drugs are synthetic analogues of pyrophosphate and inhibit 
osteoclast-mediated bone resorption [2, 3]. All bisphosphonates have demonstrated 
an increase in BMD in postmenopausal osteoporosis [4-7]. However, only alendronate 
and risedronate have a proven effect in the reduction of vertebral and peripheral 
fractures [5, 7].
Gastrointestinal complaints are the most common side effects of oral bisphosphonates 
[5, 7-10]. The large randomized clinical trials (RCTs) investigating oral daily 
alendronate in postmenopausal women with osteoporosis showed incidence rates 
of upper gastrointestinal adverse events of between 22% and 48% [8-10]. Although 
the incidence rates in the placebo groups were comparable, these data still indicate 
that dyspepsia is an important issue in the treatment of patients with osteoporosis. In 
addition to oral administration, pamidronate can also be given through intravenous 
infusion. Therefore, pamidronate is frequently used in daily practice for patients who 
cannot tolerate oral bisphosphonates, in spite of the lack of anti-fracture data during 
intravenous use of pamidronate.
Prospective studies in the treatment of naïve osteoporosis patients, comparing an 
intravenous bisphosphonate with an oral one, are lacking. Since it is inconceivable that 
such a randomized study will be performed, we observed the changes in BMD (spine 
and hip) in daily clinical practice during 1 year of treatment with either alendronate 
10 mg/day or intravenous pamidronate 60 mg/3 months. 
PATIENTS AND METHODS 
Since 2000, Slotervaart Hospital (Amsterdam, the Netherlands) has had an outpatient 
clinic for patients with osteoporosis. Data are gathered prospectively and systematically 
in this clinical practice setting. Patients referred to this clinic are screened routinely 
for osteoporosis and receive treatment when indicated. Patients who are treated with 
anti-osteoporotic drugs return for a routine follow-up visit each year. 
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Forty consecutive patients attending the osteoporosis clinic who were started on 
treatment with either oral alendronate 10 mg/day or intravenous pamidronate 60 mg/3 
months were included in the study. Twenty patients were allocated to each group. 
The first choice for bisphosphonate treatment of osteoporosis was oral alendronate. 
Intravenous pamidronate was given to patients with gastrointestinal contraindications 
for oral bisphosphonate (n=9) or with intolerance of oral bisphosphonate (within 1 
month of initiation of bisphosphonate therapy, n=11). Patients with previous treatment 
for longer than 1 month with anti-osteoporosis drugs were not included.
If the dietary intake of calcium was below 1,000 mg/day, patients received supple-
mentation with calcium. Thirteen patients in the alendronate group and 17 in the 
pamidronate group received calcium supplementation. Vitamin D supplementation 
(colecalciferol 400 U/day) was given in patients whose serum 25(OH) vitamin D level 
was below 30 nmol/l at baseline. In each group seven patients received supplementation 
with colecalciferol. 
Assessments
Demographic data and data on risk factors for osteoporosis were collected by 
questionnaire at baseline and after 1 year. Data collected comprised: age, body mass 
index (BMI), menopausal status, history of fractures, family (first degree) history 
of fractures (vertebral and peripheral fractures), thyroid function, kidney function, 
current medication (including prednisone) and history of prednisone use.
BMD was measured with dual X-ray absorptiometry (DEXA) at the lumbar-
spine (L1–L4) and the total hip at the start of treatment and after 1 year. All BMD 
measurements were performed with the same equipment (Hologic 4500, Waltham, 
MA, USA).
Statistics
To compare the distribution of risk factors for osteoporosis between groups we used 
Pearson’s chi-square test for dichotomous variables and Student’s t-test for continuous 
variables. Changes in BMD between the groups and in the groups were compared by 
an independent and paired Student’s t-test, respectively. The data were analyzed with 
the SPPS 11.1 software package. A p-value below 0.05 was considered statistically 
significant.
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RESULTS
The patient characteristics are shown in Table 1. There were no significant differences 
between the groups in age, BMI, gender, use of prednisone, thyroid and kidney function 
(data not shown), history of fractures or family history of fractures. The BMD of the 
spine and the total hip at baseline were also comparable between the alendronate and 
pamidronate groups (Table 2).
There was no difference in risk factors and baseline BMD between the patients treated 
with intravenous pamidronate because of gastrointestinal co-morbidity and those with 
gastrointestinal intolerance of oral bisphosphonate.
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Table 1 Epidemiological data and risk factors for osteoporosis in the alendronate and 
pamidronate groups
Parameter
Alendronate Pamidronate
10 mg/day 
per os
60 mg/3 months 
intravenous
n=20 n=20
Age Mean (SD) 68.5 (15.4) 67.3 (15.7) NS
BMI Mean (SD) 25.9 (5.5) 23.7 (3.2) NS
Gender (female) n (%) 15 (75) 16 (67) NS
Post menopausal n (%) 14 (93) 15 (88) NS
Fractures (history) (vertebral and peripheral) n (%) 11 (55) 8 (40) NS
Familial fractures n (%) 8 (40) 10 (50) NS
Calcium intake (mg/day) Mean (SD) 1,055 (465) 1,070 (470) NS
Vitamin D concentration (nmol/l) Median (range) 60 (3–120) 57 (5–110) NS
Prednisone (history)
Ever used prednisone n (%) 5 (25) 5 (25)
Current use of prednisone n (%) 5 (25) 6 (30) NS
Never used prednisone n (%) 10 (50) 9 (45)
Table 2 Baseline BMD data (mean [SD]) in the alendronate and pamidronate groups
Parameter Alendronate group Pamidronate group
Vertebral spine
BMD (g/cm2) 0.819 (0.167) 0.748 (0.150) NS
t-score -2.05 (1.18) -2.79 (1.36) NS
z-score -0.53 (1.33) -1.06 (1.47) NS
Total hip
BMD (g/cm 2) 0.720 (0.133) 0.704 (0.135) NS
t-score -1.55 (0.73) -2.05 (1.10) NS
z-score -0.59 (0.88) -0.81 (1.13) NS
BMD change
The increase in BMD of the vertebral spine in both groups was comparable. The BMD 
of the lumbar spine increased significantly in both groups: 0.032 g/cm2 (+4.0%, p<0.001 
vs baseline) in the alendronate group and 0.028 g/cm2 (+4.0%, p<0.05 vs baseline) in 
the pamidronate group. According to total hip measurements the BMD increased 
significantly in both the alendronate and the pamidronate groups: 0.025 g/cm2 (3.3%) 
and 0.018 g/cm2 (+2.9%) (both p<0.05 vs baseline), respectively. The difference in 
change in BMD of the hip between the alendronate and pamidronate groups was not 
statistically significant. 
DISCUSSION
This study shows that, in patients visiting our osteoporosis clinic, treatment with 
intravenous pamidronate is as effective as treatment with oral alendronate, measured 
by the effect on BMD. Therefore, we suggest that intravenous pamidronate is an 
alternative for patients who cannot tolerate oral bisphosphonate or have gastrointestinal 
contraindications for these drugs. We realize that our study population may be 
subject to selection bias; patients receiving intravenous pamidronate were selected 
because of gastrointestinal problems. It is possible that those patients differed from 
the alendronate-treated patients who did not have gastrointestinal intolerance or co-
morbidity. However, the positive effects on BMD in the alendronate group were also 
observed in the pamidronate group, which suggests that pamidronate is an acceptable 
alternative to alendronate in these patients.
Upper gastrointestinal adverse events are common during treatment with oral bisphos-
phonates [4]. After the introduction of alendronate a post-marketing surveillance study 
showed that alendronate could cause chemical esophagitis, with severe ulceration [8, 
11]. Based on the data presented in that report, the dosing instructions were altered 
to reduce esophagitis. Those instructions greatly reduced the number of upper 
gastrointestinal adverse events. Large RCTs on the use of oral bisphosphonates suggest 
that the incidence rates of upper gastrointestinal complaints in alendronate and placebo 
are now roughly the same [8-10]. However, these data apply to large cohorts of selected 
patients. In daily clinical practice the intolerance of oral bisphosphonates is still a 
major issue for the physician treating osteoporosis patients. Therefore, we frequently 
use intravenous pamidronate in those osteoporosis patients.
Low compliance is an issue in the treatment of all chronic diseases [12]. Osteoporosis 
is a chronic disease and anti-osteoporotic drugs have to be taken for a long period of 
time. Poor adherence limits the effect of bisphosphonates, which makes compliance 
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an important problem in treatment with bisphosphonates [13]. A few studies have 
investigated the compliance with bisphosphonates for the treatment of osteoporosis in 
daily practice. One study found a discontinuation rate as high as 30% during the first 
half year of treatment with oral bisphosphonates [14]. Intravenous administration of 
pamidronate provides certainty that patients receive their anti-osteoporotic treatment 
and gives more control over patients’ compliance.
We investigated the effect of bisphosphonates on BMD. Although BMD is used as a 
surrogate endpoint for studies in osteoporosis, the primary goal of treatment remains 
fracture reduction. However, if the efficacy of anti-osteoporotic agents on fracture 
rates is to be to properly evaluated, a very large study population is needed. To show a 
clinically and statistically significant difference between two anti-osteoporotic drugs, 
a study would have to include approximately 100,000 patients. A study with such a 
sizable population is almost impossible to perform [15]. In addition, a low BMD is the 
most important risk factor to predict fractures. Although weak, associations between 
changes in BMD and reductions in vertebral and peripheral fractures have been shown 
during treatment with bisphosphonates [16, 17]. Our study was performed in small 
groups and only comprises BMD data; nevertheless, this is the first prospective study 
comparing intravenous bisphosphonate with an oral bisphosphonate in one study.
In summary, the effect on BMD of oral alendronate and intravenous pamidronate is 
comparable. Therefore, we conclude that intravenous pamidronate is an acceptable 
alternative to oral bisphosphonates in the treatment of osteoporosis for patients who 
cannot tolerate an oral bisphosphonate or have gastrointestinal contraindications for 
these drugs. 
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Summary and discussion
Chapter 9
In the first part of this thesis investigations are reported on generalized bone loss in 
patients with rheumatoid arthritis. In the second part, several studies are described 
that we performed in our cohort of patients with rheumatoid arthritis (RA) treated 
with infliximab, a TNFα-blocking agent. 
PART I 
In chapter 2 data are reported on the effects of infliximab on bone and bone metabolism 
in patients with RA. In chapter 2A the short-term effects of infliximab on bone 
metabolism in a cohort of 68 RA patients are shown. In this study bone formation 
was measured by osteocalcin (OC), N-terminal peptide of type 1 procollagen (PINP) 
and bone specific alkaline phosphatase (BALP), whereas bone resorption was 
measured by  β-isomerized carboxy terminal telopeptide of type 1 collagen (β-CTX) 
and carboxy terminal peptide of type I collagen (ICTP). Both OC and PINP showed 
a significant increase and β-CTX a significant decrease during 14 weeks of treatment 
with infliximab. These changes in bone resorption (β-CTX) were correlated with the 
change in disease activity (DAS-28). 
In chapter 2B data are presented on the effect of 1 year of treatment with infliximab on 
BMD (spine, hips and hands) and markers of bone metabolism in a cohort of 102 RA 
patients. In this study, treatment with infliximab arrested generalized bone loss in hips 
and lumbar spine, whereas localized bone loss in hands, measured with digital X-ray 
radiogrammetry (DXR), persisted (-0.8%, p<0.01). In patients with a good clinical 
response to treatment defined by the EULAR response criteria, there was an increase 
of BMD in hip and spine, whereas there was a decrease of BMD in patients who had a 
less favourable clinical response. This relationship between disease activity and bone 
loss was further supported by the correlation between change in DAS-28 and CRP 
with β-CTX. Receptor activator of NFκb ligand (RANKL), an activator of osteoclast 
differentiation and activation, decreased significantly whereas osteoprotegerin (OPG) 
remained stable, leading to a favourable change in its ratio. 
In conclusion, treatment with infliximab reduces bone resorption whereas it increases 
bone formation in patients with rheumatoid arthritis, subsequently arresting 
generalized bone loss. However, localized bone loss in hands persists.
Chapter 3 describes the changes of BMD in spine, hip and hands and the occurrence 
of fractures in patients with rheumatoid arthritis over a period of 5 years. This project 
was performed by the OSTRA-group. Five years ago the OSTRA-group established 
a cohort of 150 female RA patients with an established disease (> 5 years). The main 
result of the baseline study was that a low BMD in hip and vertebral fractures was 
associated with radiological damage of the joints (total Larsen-score), in addition to 
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other well-known determinants: high age, low BMI, and high cumulative doses of 
corticosteroids.
In total, 102 out of these 150 patients were included in the 5-year follow-up study. 
Chapter 3a describes the fractures that occurred during the follow-up period. It shows 
that there was a high rate of vertebral and non-vertebral fractures during those 5 years. 
A total of 18 out of 102 patients (17.6%) sustained a new non-vertebral fracture during 
follow-up and in 18 out of 97 patients (18.5%) new vertebral fractures were identified 
on spinal X-rays. This resulted in an annual incidence rate of 3.2 (95% CI 1.8–5.5) 
per 100 patients years for non-vertebral fractures and of 3.7 (95% CI 2.2–5.8) per 100 
patients years for morphometric vertebral fractures. These incidence rates are higher 
than those found in general population in individuals of the same age and gender: 
1.9/100 patient years and 0.8 to 1.0/100 patient years respectively [1-4].
Furthermore, a substantial decrease in BMD was observed in hip and spine during the 
follow-up period (chapter 3b). There was a significant decrease of 5.9% (p<0.05) in 
total-hip BMD (g/cm2) and in spine (L2–L4) there was a trend towards a loss (-2.4%, 
p=0.059). Again, this is higher than the rate of BMD loss found in general population. 
The loss of cortical hand BMD measured by DXR from hand radiographs, is described 
in chapter 3b. The mean (95% CI) DXR-BMD change was -6.7% (-11.2, -2.82%). In 
this study high disease activity at baseline measured by DAS-28 was an independent 
predictor for cortical hand bone loss over a period of 5 years. 
The conclusions of the studies described in chapter 3 show a substantial amount of 
bone loss and a high risk of fractures in postmenopausal women with RA. This is 
remarkable, since modern anti-rheumatic therapies like TNF blocking agents and 
effective anti-osteoporotic drugs, such as bisphosphonates, are widely available. This 
implicates that rheumatologists need to pay more attention to osteoporosis when 
treating RA patients, by aiming at disease remission and using bisphophonates more 
frequently.
PART II
In the second part of this thesis data are presented on several studies undertaken in 
our cohort of infliximab-treated RA patients. This cohort was established at the Jan 
van Breemen Institute, Slotervaart hospital and VU University medical center (all 
situated in Amsterdam, the Netherlands) in 2001, at the start of the introduction 
of infliximab in the Netherlands. All consecutive patients treated with infliximab 
were included into this cohort. Patients were followed for disease activity and side 
effects, blood samples were taken at each visit and X-rays and a DEXA-scan were 
performed yearly.
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Patients with RA have an increased risk of morbidity and mortality compared to general 
population. Mortality due to cardiovascular disease (CVD) is the main cause of death 
in patients with RA. This excess of cardiovascular mortality in patients with RA is 
predominantly due to accelerated atherosclerosis, possibly induced by inflammation 
in RA. There is evidence that inflammation in RA is associated with a worsening of 
the lipid profile [5, 6]. 
In chapter 4a data are presented on the short-term effect of infliximab treatment on 
lipid profiles during the first 14 weeks. It was found that treatment with infliximab 
led to a significant increase of both total- and HDL-cholesterol levels 0.4mmol/l and 
0.1mmol/l, respectively. These changes were inversely related to the change in disease 
activity. However, the atherogenic index (ratio between total- and HDL-cholesterol), 
an important prognostic indicator for future CVD, remained constant.
Chapter 4b describes the long-term effect of infliximab on lipid levels in RA patients. 
In this study we observed a significant increase of total- and HDL-cholesterol levels 
after 6 weeks of infliximab treatment, which gradually returned to baseline after 48 
weeks. Longitudinal analyses revealed significant, yet opposite, associations between 
lipid levels and disease activity and between lipid levels and prednisone dose. DAS-28 
improvement by 1 point is associated with an increase of 0.016 mmol/l (0.618 mg/
dl) total- and 0.045 mmol/l (1.737 mg/dl) HDL-cholesterol. Reduction of 10 mg of 
prednisone is associated with a decrease of 0.04 mmol/l (1.544 mg/dl) total- and 0.16 
mmol/l (6.177 mg/dl) HDL-cholesterol. The initial beneficial effect of infliximab on 
the lipid profile, a reduction of disease activity, seems to be attenuated by a concomitant 
decrease in prednisone dose. 
Chapter 4 implicates that the inflammation in RA leads to changes in cholesterol, 
although the reduction of inflammation by infliximab does not directly lead to an 
improvement in lipid profile (no change in atherogenic index).
One of the characteristics of RA is the presence of auto-antibodies. IgM-RF is observed 
in about 75% of RA patients, but it is also frequently observed in other inflammatory 
diseases. Antibodies against cyclic citrullinated peptide (anti-CCP) target citrullinated 
proteins and are highly specific for RA and present in about 80% of RA patients [7, 8].
These antibodies are also found years before the onset of the disease. That is why anti-
CCP is often considered as indicators for the pathogenesis of RA.
Chapter 5 shows that in our cohort of RA patients treated with infliximab over a 
period of one year, both IgM-RF and anti-CCP had decreased significantly. Antibodies 
against deiminated fibrinogen, a specific citrullinated peptide that is found in inflamed 
joints of RA patients, also decreased significantly. In terms of percentages, the levels 
of IgM-RF were reduced by 64%, whereas the anti-CCP and ACF levels were reduced 
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by roughly 25%. ACF levels showed a large decrease in patients with a short disease 
duration. These data would imply that if auto-antibodies in RA really have a pathogenic 
role, that treatment with infliximab, especially early treatment, could alter the onset 
of the disease.
Treatment with infliximab provides great benefit for many patients with rheumatoid 
arthritis. However, some patients have a persistent active disease whereas others 
show loss of efficacy after prolonged treatment. Infliximab, which is a chimeric 
monoclonal antibody (partly human, partly mouse), may induce IgG-auto-antibodies 
that may cause loss of efficacy and may lead to allergic reactions [9, 10]. The results 
presented in chapter 6 show that antibodies against infliximab were detected in 22 
patients (43%). Patients with anti-infliximab antibodies were significantly more often 
classified as non-responders to treatment, compared to patients without detectable 
anti-infliximab antibodies (20/29 69%; versus 8/22 (36%), p=0.04). In addition, anti-
infliximab antibodies could be detected in all patients with an allergic reaction (n=3). 
In conclusion, treatment with infliximab may induce anti-infliximab antibodies, which 
may lead to loss of efficacy and may cause allergic reactions to infliximab. 
Infliximab is considered to be relatively safe in randomized controlled trials for the 
registration of the drug [11]. However, this could be different in daily clinical practice, 
because of patient selection in randomized clinical trials. That is why we determined the 
adverse events, in particular infections, in RA patients treated with infliximab in daily 
clinical practice, who usually have more co-morbidity and co-medications than trial 
patients. These findings are reported in chapter 7. Patients frequently had infections 
(43–57%, depending on the definition used), mostly on the upper respiratory tract and 
the lower urinary tract. The incidence of serious infections was 0.08/patient-year. These 
numbers are comparable to the infection rates found in randomized trials, indicating 
that infliximab can be safely administered in daily clinical practice.
Gastro-intestinal complaints are the most common side effects of oral bisphosphonates. 
Therefore, pamidronate can be an attractive alternative for those patients who do 
not tolerate oral bisphosphonates, or for those who have a severe contra-indication 
for them [12, 13]. In chapter 8 the changes in BMD are described during one year of 
treatment with intravenous pamidronate (60 mg every 3 months) in patients who do 
not tolerate oral bisphophonates, compared to patients who do and who are treated 
with alendronate. This study shows that in patients visiting our osteoporosis clinic, 
treatment with intravenous pamidronate was as effective as treatment with oral 
alendronate, measured by the effect on BMD. The BMD of lumbar spine increased 
by 4.0% (p<0.05 vs baseline) in both groups, and the BMD of hip increased by 
3.3% and 2.9% (p<0.05 vs baseline) in the alendronate and pamidronate groups, 
respectively. 
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Generalized bone loss is an important extra-articular of rheumatoid arthritis. In our 
OSTRA-cohort, patients were treated according to modern treatment concepts, including 
the use of TNF-blockers and combination therapy, however, there was still a high rate of 
bone loss. BMD in spine and hips decreased significantly and there was a high incidence 
of vertebral and non-vertebral fractures: one fifth of the female patients with established 
RA suffered a vertebral fracture and another 19 percent a non-vertebral fracture during 
a 5 years observational period. These fractures will contribute to a decrease in quality of 
life for these patients. Effective anti-osteoporotic therapies are available for the prevention 
of fractures. It is therefore important for rheumatologists to focus on the prevention of 
generalized bone loss, particularly in those patients who are at high risk of fractures: 
elderly women, prednisone users, and patients with a very active disease.
Furthermore, treatment with a TNF-blocker seems to arrest generalized bone loss in 
RA patients, but it does not arrest localized bone loss. We established a relation between 
disease activity and generalized bone loss. This could implicate that, with the new anti-
rheumatic treatment strategies and biologicals, less osteoporosis will be observed in 
RA patients. However, continuing bone loss in hands during effective anti-rheumatic 
treatment could also imply that inflammatory control alone is not sufficient. It may be 
necessary to add adjuvant bone protection to anti-inflammatory treatment. Bone loss 
in rheumatoid arthritis is characterized by an increase of bone resorption. Bisphosp-
honates are potent inhibitors of osteoclast activity and could therefore be an attractive 
candidate for such an adjuvant therapy. There is already evidence that bisphosphona-
tes are effective in the prevention of erosions in animal and human studies [14, 15]. 
Another interesting drug could be denosumab, a biological that blocks RANKL and, 
consequently osteoclast differentiation and activation. In this thesis we have shown 
that there is increased expression of RANKL in active RA. Other studies have shown 
increased levels of RANKL in inflamed joints of RA patients. Also blocking RANKL 
in animal models has prevented joint erosions without influencing inflammation 
[16]. A pilot study in RA patients showed similar but slightly disappointing results 
[17]. There is also some evidence that the WNt signalling pathway is involved in the 
repair of erosions. Blocking antagonists of Wnt, such as sclerostin and dickopf1, with 
antibodies prevents the development of erosions in experimental animal models of 
rheumatoid arthritis [18]. However, future investigations are needed to clarify the 
relationship between local bone loss and inflammation and to determine whether 
adjuvant therapies could be beneficial for RA patients. 
The studies in this thesis are cohort studies without appropriate control groups, which 
makes it hard to draw definite conclusions from them. However they raise questions 
for further research to expand and elucidate the results.
134
Summary and discussion
Most of the studies in part two have led to further investigations within our department. 
This is especially true for example for the implication of antibodies against infliximab 
in the loss of efficacy of infliximab during treatment. These neutralizing antibodies 
are also detected in patients with other rheumatic diseases than RA (psoriatic arthritis 
and ankylosing spondylitis and they also lead to loss of efficacy in these patient groups 
[19, 20]. New essays were developed to detect auto-antibodies for other biologicals. 
(adalimumab and rituximab) Further studies have also shown that patients who de-
veloped auto-antibodies for infliximab could successfully be switched to adalimumab. 
These patients even responded better to adalimumab than patients who had an initial 
low response to infliximab [21].
Determination of antibodies against TNF blockers is now frequently used to decide 
about continuation of therapy. However, future studies are needed to further clarify 
the clinical use of these antibodies.
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Samenvatting
Reumatolde artritis: 
biologicals en bot
¨
Chapter 10
In deel I van dit proefschrift worden resultaten gepresenteerd van onderzoek naar 
gegeneraliseerd botverlies (osteoporose) in patiënten met reumatoïde artritis (RA). In 
deel II worden diverse studies beschreven die wij verricht hebben in ons cohort 
van patiënten met reumatoïde artritis, die behandeld werden met moderne anti-
reumatische therapie; TNF-blokkers, in ons geval infliximab. 
DEEL I 
Reumatoïde artritis is een ziekte die gepaard gaat met schade aan de gewrichten. Hierbij 
is er niet alleen verlies van bot dat het gewricht vormt, maar is er ook gegeneraliseerd 
botverlies (osteoporose). Dit verlies van bot lijkt niet alleen geassocieerd met de 
activiteit van de ziekte, maar ook bijvoorbeeld met de medicatie die gebruikt wordt om 
reumatoïde artritis te behandelen (prednison). In het eerste deel van dit proefschrift 
worden enkele onderzoeken beschreven naar dit gegeneraliseerde botverlies bij 
RA.
In hoofdstuk 2a worden de korte-termijneffecten (14 weken) van infliximab op bot-
metabolisme in patiënten met RA beschreven. De mate van botaanmaak en botafbraak 
werd bepaald met behulp van markers in het bloed voor beide processen. De markers 
voor botaanmaak vertoonden een lichte stijging en de markers voor botafbraak lieten 
een aanzienlijke daling zien gedurende de 14 weken van behandeling. De daling in 
botafbraakmarkers was gecorreleerd met een afname van de ziekteactiviteit. 
In hoofdstuk 2b zijn de gegevens te zien van het effect van 1 jaar behandeling 
met infliximab op de botmineraaldichtheid (BMD) van wervelkolom, heupen en 
handen en op de markers van botmetabolisme in een cohort van 102 patiënten met 
reumatoïde artritis. Deze studie toonde aan dat door behandeling met infliximab het 
gegeneraliseerde botverlies in de heupen en de lumbale wervelkolom kon worden 
voorkomen. Echter, het lokale botverlies in de handen kon niet worden voorkomen. Bij 
patiënten met een goede klinische respons op de behandeling met infliximab (volgens 
de EULAR responscriteria), was er een lichte toename in BMD van de heup en de 
wervelkolom, terwijl er bij patiënten met een matige klinische respons een daling 
van de BMD te zien was. Deze relatie tussen ziekteactiviteit en botverlies werd 
verder ondersteund door de correlatie tussen afname in ziekteactiviteit (DAS-28 
en CRP) en een daling van een marker voor botafbraak (ß-CTX). Tevens daalde 
de concentratie van een belangrijk eiwit (RANKL), dat een belangrijke rol speelt in 
de differentiatie, activering en overleving van botafbrekende cellen (osteoclasten) 
aanzienlijk gedurende de behandeling met infliximab. De blokker van dit eiwit (OPG) 
bleef echter stabiel in concentratie. Dit resulteerde in een gunstige verandering in de 
ratio van beide botafbraak regulerende eiwitten (RANKL/OPG). 
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Samengevat, behandeling met infliximab vermindert de botafbraak in patiënten met 
RA, wat leidt tot een vermindering van gegeneraliseerd botverlies. 
In hoofdstuk 3 worden veranderingen beschreven in de BMD van de wervelko-
lom, heup en handen en het optreden van fracturen gedurende 5 jaar bij patiënten 
met reumatoïde artritis. Dit onderzoek is uitgevoerd door de OSTRA-groep. De 
OSTRA-groep is een internationale onderzoeksgroep die bestaat uit reumatologen 
uit 3 Noord-Europese landen: Oslo (Noorwegen), Truro (Verenigd Koninkrijk) 
en Amsterdam (Nederland). De OSTRA-groep onderzoekt verschillende aspecten 
van botmetabolisme bij patiënten met reumatische ziektes. Het OSTRA-cohort is 
een cohort dat bestaat uit 150 vrouwelijke RA-patiënten met gevorderde ziekte (> 5 
jaar). Het belangrijkste resultaat van de eerder beschreven baselinestudie van dit co-
hort was, dat ernstige gewrichtsschade (gemeten door de Larsen-score) geassocieerd 
was met een lage BMD van de heup en een toename van wervelfracturen. In totaal 
werden 102 van deze 150 patiënten na 5 jaar opnieuw onderzocht en geïncludeerd 
in de follow-upstudie.
In hoofdstuk 3a volgt een beschrijving van fracturen die zich bij deze patiënten 
hebben voorgedaan tijdens de follow-upperiode. We ontdekten dat een groot aantal 
nieuwe wervel- en niet-wervelfracturen optrad gedurende die 5 jaar. Bij 18 van de 
102 patiënten (17,6%) had zich een nieuwe, niet-wervelfractuur voorgedaan en bij 18 
van 97 patiënten (18,5%) kon een nieuwe wervelfractuur worden geïdentificeerd op 
de foto van de wervelkolom. Dit komt neer op een jaarlijkse incidentie van 3,1 per 100 
patiënten voor nieuwe niet-wervelfracturen en van 3,7 per 100 patiënten voor nieuwe 
wervelfracturen. Dit is duidelijk hoger dan de incidentie die doorgaans wordt gevonden 
in de algemene bevolking van vergelijkbare leeftijd en geslacht. 
Bovendien vonden we een aanzienlijke daling van de BMD van de heup en de wer-
velkolom tijdens de 5 jaar follow-upperiode (hoofdstuk 3b). Er was een statistisch 
significante daling van 5,9% (p<0,05) van de BMD van de heup. Ook het verlies van 
BMD was groter dan verwacht mag worden in een populatie met vergelijkbare leeftijd 
en geslacht. 
In hoofdstuk 3c wordt de verandering van BMD van de handen beschreven die we 
hebben gemeten met dual X-ray radiogrammatry (DXR). Er was een afname in de 
gemiddelde DXR-BMD van 6,7%. Hoge ziekteactiviteit aan het begin van de studie 
was een voorspeller voor verlies van BMD van de hand, gedurende de periode van 5 
jaar. 
Concluderend, er is bij RA-patiënten een toegenomen verlies van BMD met daarbij 
een verhoogde incidentie van wervel- en niet-wervelfracturen.
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DEEL II
In het tweede deel van het proefschrift wordt een aantal studies gepresenteerd, die 
wij hebben verricht in ons cohort van de met infliximab (TNF-blokker) behandelde 
RA-patiënten. Dit cohort werd opgestart in het Slotervaartziekenhuis en het VU 
medisch centrum in 2001, kort na de introductie van infliximab in Nederland. Alle 
patiënten die behandeld werden met infliximab, werden geïncludeerd in dit cohort. 
Ziekteactiviteit en bijwerkingen werden structureel bijgehouden, bloedmonsters 
werden afgenomen bij elk bezoek en röntgenfoto’s van handen en voeten werden 
jaarlijks verricht.
Patiënten met RA hebben een verhoogde mortaliteit in vergelijking met de algemene 
bevolking. Sterfte ten gevolge van hart- en vaatziekten (HVZ) is de belangrijkste 
oorzaak van de toegenomen sterfte bij patiënten met RA. Deze hoge incidentie van 
cardiovasculaire mortaliteit bij patiënten met RA lijkt voornamelijk het gevolg van 
versnelde atheroclerose. Er is tevens bewijs dat de ontsteking bij RA is geassocieerd 
met een verslechtering van het lipidenprofiel. In hoofdstuk 4a worden gegevens 
gepresenteerd van de korte-termijneffecten van de behandeling met infliximab op 
het lipidenprofiel in patiënten met RA. De behandeling met infliximab leidde tot 
een statistisch significante toename van zowel het totaal-cholesterol als het HDL-
cholesterol. Deze veranderingen waren omgekeerd evenredig met de verandering in 
de ziekteactiviteit. Echter, de atherogene index (verhouding tussen totaal-cholesterol 
en HDL-cholesterol), een belangrijke prognostische indicator voor toekomstige hart- 
en vaatziekten, bleef onveranderd. 
In hoofdstuk 4b worden de effecten op de langere termijn (1 jaar) van infliximab 
op het lipidenprofiel in RA-patiënten gepresenteerd. In deze studie zagen we een 
aanzienlijke toename van het totaal-cholesterol en HDL-cholesterol in de eerste 6 
weken van behandeling met infliximab, waarna deze vervolgens geleidelijk terugzakten 
tot de uitgangswaarde. Uit analyses bleek, dat er een tegenovergesteld effect was op 
de lipidenspiegels tussen ziekteactiviteit en prednisondosis. Een vermindering van 
de ziekteactiviteit was geassocieerd met een toename in totaal-cholesterol en HDL-
cholesterol. Een afname van prednison was echter geassocieerd met een daling van 
totaal-cholesterol en HDL-cholesterol. Het lijkt er dus op dat de initiële effecten van 
infliximab op het lipidenprofiel door een vermindering van de ziekteactiviteit teniet 
worden gedaan door een verlaging van de prednisondosis omdat de ziekteactiviteit 
is afgenomen. 
Samenvattend kan worden gesteld dat er een duidelijk effect van infliximab op het 
lipidenprofiel is door vermindering van de ziekteactiviteit. Deze verandering leidt 
echter niet tot een minder atherogeen lipidenprofiel. 
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Eén van de kenmerken van RA is de aanwezigheid van auto-antilichamen; IgM-reuma-
factor en anti-CPP. Anti-CCP antistoffen zijn antistoffen gericht tegen gecitrulineerde 
eiwitten en zijn zeer specifiek voor patiënten met RA. Van anti-CCP antistoffen wordt 
gedacht dat ze mogelijk ook een rol spelen bij het ontstaan van RA, mede omdat deze 
antistoffen al voorkomen bij patiënten voordat de ziekte zich openbaart. In hoofdstuk 
5 wordt aangetoond dat in ons cohort van RA-patiënten die gedurende een jaar be-
handeld werden met infliximab, zowel de IgM-RF- als de anti-CCP-titer aanzienlijk 
gedaald waren. Ook antistoffen tegen gedeimineerd fibrinogeen (ACF), een specifiek 
gecitrullineerde peptide die in het bijzonder gevonden wordt in ontstoken gewrichten 
van RA-patiënten, daalden aanzienlijk. In termen van percentages daalde de IgM-RF-
titer met 64%, terwijl de anti-CCP- en ACF-niveaus werden verminderd met ongeveer 
25%. ACF-niveaus toonden een grotere daling bij patiënten met vroege ziekte (ziekte 
van korte duur). Dit zou kunnen duiden op een mogelijk “window of opportunity” 
voor beïnvloeding van het ontstaan van RA.
Behandeling met infliximab is zeer effectief bij veel RA-patiënten. Echter, bij sommige 
patiënten treedt er een verlies van werkzaamheid op na een periode van succesvolle 
behandeling. Infliximab is een medicament dat niet volledig lichaamseigen is (deels 
mens, deels muis); waardoor er antistoffen tegen infliximab kunnen ontstaan. Door 
deze antistoffen zou er verlies van werkzaamheid kunnen optreden en zouden er 
bijwerkingen kunnen ontstaan. Uit de resultaten gepresenteerd in hoofdstuk 6 blijkt 
dat antilichamen tegen infliximab konden worden aangetoond in het bloed van 22 
patiënten (43%) behandeld met infliximab. Patiënten met anti-infliximab antistoffen 
werden significant vaker gevonden in de groep die niet goed reageerde op infliximab 
in vergelijking met de groep patiënten die wel een goede reactie vertoonde na 14 
weken. Opmerkelijk is, dat bij alle patiënten met een allergische reactie (n=3) anti-
infliximab antistoffen konden worden aangetoond. 
Anti-infliximab antistoffen kunnen dus leiden tot verlies van effectiviteit en kunnen 
allergische reacties veroorzaken bij het gebruik van infliximab.
In de registratiestudies is infliximab naast een effectieve ook een veilige behandeling 
voor patiënten met RA. Deze gegevens kunnen echter niet altijd vertaald worden 
naar de dagelijkse praktijk vanwege de selectie van relatief gezonde patiënten in 
gerandomiseerde klinische studies. Daarom hebben wij alle infecties onderzocht 
in ons cohort waarin het gaat om patiënten uit de dagelijkse praktijk die behandeld 
worden met infliximab (hoofdstuk 7). Veel patiënten maakten minimaal één infectie 
door (43–57%, afhankelijk van de gebruikte definitie); meestal waren dit infecties van 
de bovenste luchtwegen en de urinewegen. De incidentie van ernstige infecties was 
0,08 per patiënt/jaar. Deze getallen zijn hoger dan voor de algemene populatie, maar 
vergelijkbaar met de infectiefrequenties die gevonden werden in gerandomiseerde 
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studies naar infliximab bij patiënten met een reumatische aandoening. Hieruit blijkt 
dat infliximab relatief veilig is in de dagelijkse klinische praktijk. 
Gastrolintestinale klachten zijn de meest voorkomende bijwerkingen van orale bisfos-
fonaten zoals alendronaat en risedronaat. Het bisfosfonaat pamidronaat kan echter ook 
worden toegediend middels intraveneuze infusie. Daarom wordt er gebruik gemaakt 
van pamidronaat voor patiënten die orale bisfosfonaten niet kunnen verdragen. In 
hoofdstuk 8 worden de veranderingen in BMD gedurende 1 jaar behandeling met 
intraveneus pamidronaat (60 mg elke 3 maanden) beschreven bij patiënten die orale 
bisfosfonaten niet tolereren, in vergelijking met patiënten die ze wel verdragen en die 
worden behandeld met alendronaat. Deze studie toont aan, dat de behandeling met 
intraveneus pamidronaat net zo effectief is als orale behandeling met alendronaat, 
gemeten door het effect op de BMD. 
144
Samenvatting
Dankwoord 
(Acknowledgements)
Dit proefschrift zou niet tot stand gekomen zijn zonder de directe of indirecte hulp 
van velen. Ik wil dan ook alle medewerkers van het VUmc, Jan van Breemen Instituut 
(thans READE) en het Slotervaartziekenhuis en vele anderen met wie ik samen heb 
gewerkt tijdens mijn promotieperiode hartelijk bedanken. Een aantal wil ik graag 
persoonlijk noemen.
Promotoren en copromotoren
Professor Lems, beste Willem, bedankt voor je aanhoudende enthousiasme over 
en inzet voor mijn promotie. Het duurde soms wat langer dan gepland voordat de 
stukken er waren, maar je bleef altijd stimulerend en positief. Tevens bedankt voor 
alle gezellige momenten, waarvan vooral de autoreis naar Kopenhagen mooie verhalen 
heeft opgeleverd.
Professor Dijkmans, hartelijk dank voor de mogelijkheid om aan uw afdeling 
promotieonderzoek te kunnen doen en voor de goede samenwerking. Tevens dank 
voor het altijd deskundige en snelle commentaar op mijn artikelen.
Dr. Wolbink, beste Gertjan, door jouw enthousiasme voor onderzoek ben ik aan deze 
promotie begonnen. Bedankt hiervoor en voor je altijd kritische commentaar en je 
unieke invalshoeken.
Dr. Voskuyl, beste Alexandre, bedankt voor je begeleiding bij dit proefschrift. Vooral 
dank voor je stimulerende commentaar bij de laatste loodjes van dit traject.
Leescommissie
Prof.dr. T.W.J Huizinga, prof.dr. P.P. Tak, prof.dr. P.P.M. Geusens, prof.dr. P.T.A. Lips, 
prof.dr. M.H.H. Kramer en prof.dr. Y.M. Smulders, hartelijk dank voor de genomen 
tijd ter beoordeling van het proefschrift.
Paranimfen
Beste Guus en Marvin, fijn dat jullie vandaag mijn paranimfen willen zijn en bedankt 
voor onze jarenlange vriendschap.
Afdeling 9b Slotervaartziekenhuis
Beste Ellen, Frank en Loes, bedankt voor de hulp bij het verzamelen van de data van 
de RA-patiënten die op de dagbehandeling behandeld werden met infliximab.
146
Dankwoord
Kamer 4A64 VUmc
Beste Gerrit, Marleen, Mariëtte, Ruud, Joost, Ernst, Irene en Mirjam, bedankt voor 
de gezellige en prettige werkomgeving op de afdeling reumatologie. Tevens bedankt 
voor de goede gesprekken over onderzoek doen, statistiek, resultaten, maar ook over 
niet-wetenschapgerelateerde onderwerpen. Gezien het feit dat jullie proefschriften 
bijna klaar dan wel klaar zijn, hebben jullie gelukkig niet al te veel last ondervonden 
van mijn geklets en van de incidentele “zuurkool met vette jus”.
Kamer B9 Jan van Breemen Instituut
Beste Vokko, Mark en Marga, bedankt voor de goede werksfeer en gezelligheid in 
het Jan van Breemen. Ondanks de ruimte van 4 bij 4 meter met 4 computers zaten 
we elkaar nooit in de weg en zijn mijn wetenschappelijke inzicht en kennis hier snel 
gegroeid. Vooral ook erg bedankt voor de fijne vriendschap die wij hadden in deze 
periode zowel tijdens als na het werk. Aan onze trip naar de EULAR in een oververhit 
(40+ °C) Lissabon heb ik een hoop goede herinneringen overgehouden.
Ook de latere onderzoekscollega’s van het JBI, Wouter, Izhar, Jenny en Mike, bedankt 
voor de goede discussies en samenwerking.
Ook de collega’s van het Laboratorium, Rob en Margret, bedankt voor jullie hulp bij 
de botmarkerartikelen en het verzamelen van spijtmateriaal. Dr. Nurmohamed, beste 
Mike, bedankt voor je inzet voor mijn proefschrift en het gebruik van je “research 
koelkast” voor een koud biertje op de vrijdagmiddagborrel.
The OSTRA Group
Dear Tore, Tony, Glenn, Espen, Pernille, Thil and Mari, thank you for the always 
friendly and inspiring meetings and the always very useful and to the point comments 
on the collaborative manuscripts. A special thanks to Espen for his hospitality during 
my trips to Oslo.
Bij het schrijven van dit boekje was er niet alleen hulp van “de professionals”, maar ook 
steun en hulp van thuis. Hiervoor veel dank en liefde, Marike, Berend en David. 
147
148
Dankwoord
About the author
CURRICULUM VITAE
Marijn Vis werd geboren op 13 december 1975 te Utrecht. In 1994 behaalde hij zijn 
VWO-diploma aan het dr. F.H. de Bruijne Lyceum in Utrecht. Van 1994 tot 2001 
studeerde hij geneeskunde aan de Vrije Universiteit in Amsterdam. Na het behalen 
van het artsexamen, begon hij als arts-onderzoeker bij de vakgroep reumatologie aan 
het VU medisch centrum onder leiding van professor B.A.C. Dijkmans en professor 
W.F. Lems. Tijdens deze periode verrichte hij werkzaamheden aan de afdelingen 
reumatologie van het Slotervaartziekenhuis, het Jan van Breemen Instituut en het 
VUmc. Voor zijn werk aan het artikel: “High incidence of vertebral and non-vertebral 
fractures in the OSTRA-cohort study: a 5 year follow-up study in postmenopausal women 
with Rheumatoid Arthritis”, ontving hij in 2010 de ECTS young investigator award. 
In 2006 startte hij met zijn opleiding tot reumatoloog als art-assistent interne 
geneeskunde in het Slotervaartziekenhuis (opleider: dr. D. Brandjes). In Januari 2009 
begon hij aan het reumatologiedeel van de opleiding in het Jan van Breemen Instituut 
(opleider: dr. D. van Schaardenburg). Sinds 2010 is hij werkzaam als arts-assistent 
reumatologie in het VU medisch centrum (opleider: dr. A.E. Voskuyl). 
Marijn Vis is getrouwd met Marike van Hengel. Zij hebben twee zoons, Berend en 
David. 
150
About the author
PUBLICATIONS
Vis M, Haavardsholm EA, Bøyesen P, Haugeberg G, Uhlig T, Hoff M, Woolf A, 
Dijkmans B, Lems WF, Kvien TK. High incidence of vertebral and non-vertebral 
fractures in the OSTRA cohort study: a 5-year follow-up study in postmenopausal 
women with rheumatoid arthritis. Osteoporos Int 2011; 13. 
Hoff M, Bøyesen P, Haugeberg G, Vis M, Woolf AD, Havaardsholm EA, Dijkmans BA, 
Kvien TK, Uhlig T, Lems WF. High disease activity is a predictor of cortical hand 
bone loss in post-menopausal patients with established rheumatoid arthritis: a 5-year 
multicentre longitudinal study. Rheumatology (Oxford) 2010; 49:1676-82.
Eekman DA, Vis M, Bultink IE, Kuik DJ, Voskuyl AE, Dijkmans BA, Lems WF. Stable 
bone mineral density in lumbar spine and hip in contrast to bone loss in the hands 
during long-term treatment with infliximab in patients with rheumatoid arthritis. 
Ann Rheum Dis 2011; 70:389-90.
Eekman DA, Vis M, Bultink IE, Derikx HJ, Dijkmans BA, Lems WF. Treatment with 
intravenous pamidronate is a good alternative in case of gastrointestinal side 
effects or contraindications for oral bisphosphonates. BMC Musculoskelet Disord 
2009; 10:86.
Bos WH, Bartelds GM, Vis M, van der Horst AR, Wolbink GJ, van de Stadt RJ, van 
Schaardenburg D, Dijkmans BA, Lems WF, Nurmohamed MT, Aarden L, Hamann 
D. Preferential decrease in IgG4 anti-citrullinated protein antibodies during 
treatment with tumour necrosis factor blocking agents in patients with rheumatoid 
arthritis. Ann Rheum Dis 2009; 68:558-63. 
Vis M, Bos WH, Wolbink G, Voskuyl AE, Twisk JW, Van de Stadt R, Hamann D, 
Dijkmans BA, Lems WF. IgM-rheumatoid factor, anti-cyclic citrullinated peptide, 
and anti-citrullinated human fibrinogen antibodies decrease during treatment with 
the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis. 
J Rheumatol 2008; 35:425-8.
Peters MJ, Vis M, van Halm VP, Wolbink GJ, Voskuyl AE, Lems WF, Dijkmans BA, 
Twisk JW, de Koning MH, van de Stadt RJ, Nurmohamed MT. Changes in lipid 
profile during infliximab and corticosteroid treatment in rheumatoid arthritis. 
Ann Rheum Dis 2007; 66:958-61. 
Vis M, Havaardsholm EA, Haugeberg G, Uhlig T, Voskuyl AE, van de Stadt RJ, 
Dijkmans BA, Woolf AD, Kvien TK, Lems WF. Evaluation of bone mineral density, 
bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand 
serum levels during treatment with infliximab in patients with rheumatoid arthritis. 
Ann Rheum Dis 2006; 65:1495-9. 
151
Wolbink GJ, Vis M, Lems WF, Voskuyl AE, de Groot E, Nurmohamed MT, Stapel S, 
Tak PP, Aarden L, Dijkmans B. Development of antiinfliximab antibodies and 
relationship to clinical response in patients with rheumatoid arthritis. Arthritis 
Rheum 2006; 54:711-5.
Vis M, Bultink IE, Dijkmans BA, Lems WF. The effect of intravenous pamidronate 
versus oral alendronate on bone mineral density in patients with osteoporosis. 
Osteoporos Int 2005;16:1432-5.
Neven N, Vis M, Voskuyl AE, Wolbink GJ, Nurmohamed MT, Dijkmans BA, Lems 
WF. Adverse events in patients with rheumatoid arthritis treated with infliximab 
in daily clinical practice. Ann Rheum Dis 2005; 64:645-6. 
Vis M, Nurmohamed MT, Wolbink G, Voskuyl AE, de Koning M, van de Stadt R, Twisk 
JW, Dijkmans BA, Lems WF. Short term effects of infliximab on the lipid profile 
in patients with rheumatoid arthritis. J Rheumatol 2005; 32:252-5.
Vis M, Voskuyl AE, Wolbink GJ, Dijkmans BA, Lems WF; OSTRA Study Group. Bone 
mineral density in patients with rheumatoid arthritis treated with infliximab. Ann 
Rheum Dis 2005; 64(2):336-7. 
Vis M, Wolbink GJ, Lodder MC, Kostense PJ, van de Stadt RJ, de Koning MH, Dijkmans 
BA, Lems WF. Early changes in bone metabolism in rheumatoid arthritis patients 
treated with infliximab. Arthritis Rheum 2003; 48:2996-7.
152
About the author
